British Society of Gastroenterology guidelines on the management of irritable bowel syndrome

Dipesh H Vasant,1,2 Peter A Paine,3 Christopher J Black,4 Lesley A Houghton,5,6 Hazel A Everitt,7 Maura Corsetti,8 Anurag Agrawal,9 Imran Aziz,10 Adam D Farmer,11,12 Maria P Eugenicos,13 Rona Moss-Morris,14 Yan Yiannakou,15 Alexander C Ford16

ABSTRACT
Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders seen by clinicians in both primary and secondary care. Since publication of the last British Society of Gastroenterology (BSG) guideline in 2007, substantial advances have been made in understanding its complex pathophysiology, resulting in its re-classification as a disorder of gut-brain interaction, rather than a functional gastrointestinal disorder. Moreover, there has been a considerable amount of new evidence published concerning the diagnosis, investigation and management of IBS. The primary aim of this guideline, commissioned by the BSG, is to review and summarise the current evidence to inform and guide clinical practice, by providing a practical framework for evidence-based management of patients. One of the strengths of this guideline is that the recommendations for treatment are based on evidence derived from a comprehensive search of the medical literature, which was used to inform an update of a series of trial-based and network meta-analyses assessing the efficacy of dietary, pharmacological and psychological therapies in treating IBS. Specific recommendations have been made according to the Grading of Recommendations Assessment, Development and Evaluation system, summarising both the strength of the recommendations and the overall quality of evidence. Finally, this guideline identifies novel treatments that are in development, as well as highlighting areas of unmet need for future research.

EXECUTIVE SUMMARY OF RECOMMENDATIONS
Doctor-patient communication
► Establishing an effective doctor-patient relationship and a shared understanding is key to the management of IBS. Such a relationship can lead to improved quality of life and symptoms, reduce healthcare visits and enhance adherence to treatment (recommendation: strong, quality of evidence: low).
► Patients with IBS would like increased empathy, support and information from clinicians about the nature of the condition, diagnosis and symptom management options (recommendation: strong, quality of evidence: low).

Diagnosis, investigation and education
► The National Institute for Health and Care Excellence guideline definition of IBS (abdominal pain or discomfort, in association with altered bowel habit, for at least 6 months, in the absence of alarm symptoms or signs) is more pragmatic and may be more applicable to patients with IBS in primary care than diagnostic criteria derived from patients in secondary care, such as the Rome IV criteria (recommendation: weak, quality of evidence: low).
► All patients presenting with symptoms of IBS for the first time in primary care should have a full blood count, C reactive protein or erythrocyte sedimentation rate, coeliac serology and, in patients <45 years of age with diarrhoea, a faecal calprotectin to exclude inflammatory bowel disease. Local and national guidelines for colorectal and ovarian cancer screening should be followed, where indicated (recommendation: strong, quality of evidence: moderate).
► Clinicians should make a positive diagnosis of IBS based on symptoms, in the absence of alarm symptoms or signs, and abnormalities on simple blood and stool tests (recommendation: strong, quality of evidence: moderate).
► Referral to gastroenterology in secondary care is warranted where there is diagnostic doubt, in patients with symptoms that are severe, or refractory to first-line treatments, or where the individual patient requests a specialist opinion (recommendation: weak, quality of evidence: low).
► There is no role for colonoscopy in IBS, other than in those with alarm symptoms or signs, or those with symptoms suggestive of IBS with diarrhoea who have atypical features and/or relevant risk factors that increase the likelihood of them having microscopic colitis (female sex, age ≥50 years, coexistent autoimmune disease, nocturnal or severe, watery, diarrhoea, duration of diarrhoea <12 months, weight loss or use of potential precipitating drugs including non-steroidal anti-inflammatory drugs, proton pump inhibitors, etc) (recommendation: strong, quality of evidence: moderate).
► In those with symptoms suggestive of IBS with diarrhoea, but with atypical features such as nocturnal diarrhoea, or a prior cholecystectomy, 23-seleno-23-homotaurocholic acid scanning or serum 7α-hydroxy-4-cholesten-3-one should be considered to exclude bile acid...
diarrhoea (recommendation: strong, quality of evidence: low).

- In patients with IBS and coexisting symptoms suggestive of a defaecatory disorder or faecal incontinence, anorectal physiology tests can be considered, where available, to select those who might benefit from biofeedback (recommendation: weak, quality of evidence: low).

- There is no role for testing for exocrine pancreatic insufficiency, or for hydrogen breath testing to rule out small intestinal bacterial overgrowth or carbohydrate intolerance, in patients with typical IBS symptoms (recommendation: strong, quality of evidence: weak).

- The diagnosis of IBS, its underlying pathophysiology and the natural history of the condition, including common symptom triggers, should be explained to the patient. This should introduce the concept of IBS as a disorder of gut-brain interaction, together with a simple account of the gut-brain axis and how this is impacted by diet, stress, cognitive, behavioural and emotional responses to symptoms, and postinfective changes (recommendation: strong, quality of evidence: weak).

**First-line treatments**

- All patients with IBS should be advised to take regular exercise (recommendation: strong, quality of evidence: weak).

- First-line dietary advice should be offered to all patients with IBS (recommendation: strong, quality of evidence: weak).

- Food elimination diets based on IgG antibodies are not recommended in patients with IBS (recommendation: strong, quality of evidence: moderate).

- Soluble fibre, such as ispaghula, is an effective treatment for global symptoms and abdominal pain in IBS, but insoluble fibre (e.g., wheat bran) should be avoided as it may exacerbate symptoms. Soluble fibre should be commenced at a low dose (3–4 g/day) and built up gradually to avoid bloating (recommendation: strong; quality of evidence: moderate).

- A diet low in fermentable oligosaccharides, disaccharides and monosaccharides and polyols, as a second-line dietary therapy, is an effective treatment for global symptoms and abdominal pain in IBS, but its implementation should be supervised by a trained diettitian and fermentable oligosaccharides, disaccharides and monosaccharides and polyols should be reintroduced according to tolerance (recommendation: weak, quality of evidence very low).

- A gluten-free diet is not recommended in IBS (recommendation: weak, quality of evidence very low).

- Probiotics, as a group, may be an effective treatment for global symptoms and abdominal pain in IBS, but it is not possible to recommend a specific species or strain. It is reasonable to advise patients wishing to try probiotics to take them for up to 12 weeks, and to discontinue them if there is no improvement in symptoms (recommendation: weak, quality of evidence: very low).

- Loperamide may be an effective treatment for diarrhoea in IBS. However, abdominal pain, bloating, nausea and constipation are common, and may limit tolerability. Titrating the dose carefully may avoid this (recommendation: strong; quality of evidence: very low).

- Certain antispasmodics may be an effective treatment for global symptoms and abdominal pain in IBS. Dry mouth, visual disturbance and dizziness are common side effects (recommendation: weak, quality of evidence: very low).

- Peppermint oil may be an effective treatment for global symptoms and abdominal pain in IBS. Gastro-oesophageal reflux is a common side effect (recommendation: weak, quality of evidence: very low).

- Polyethylene glycol may be an effective treatment for constipation in IBS. Abdominal pain is a common side effect (recommendation: weak; quality of evidence: very low).

**Second-line treatments**

- Tricyclic antidepressants used as gut-brain neuromodulators are an effective second-line drug for global symptoms and abdominal pain in IBS. They can be initiated in primary or secondary care, but careful explanation as to the rationale for their use is required, and patients should be counselled about their side-effect profile. They should be commenced at a low dose (e.g., 10 mg amitriptyline once a day) and titrated slowly to a maximum of 30–50 mg once a day (recommendation: strong, quality of evidence: moderate).

- Selective serotonin reuptake inhibitors used as gut-brain neuromodulators may be an effective second-line drug for global symptoms in IBS. As with tricyclic antidepressants, they can be initiated in primary or secondary care, but careful explanation as to the rationale for their use is required, and patients should be counselled about their side-effect profile (recommendation: weak, quality of evidence: low).

- Eluxadoline, a mixed opioid receptor drug, is an efficacious second-line drug for IBS with diarrhoea in secondary care. It is contraindicated in patients with prior sphincter of Oddi problems or cholecystectomy, alcohol dependence, pancreatitis or severe liver impairment, and lack of availability may limit its use (recommendation: weak, quality of evidence: moderate).

- 5-Hydroxytryptamine 3 receptor antagonists are efficacious second-line drugs for IBS with diarrhoea in secondary care. Alosetron and ramosetron are unavailable in many countries; ondansetron titrated from a dose of 4 mg once a day to a maximum of 8 mg three times a day is a reasonable alternative. Constipation is the most common side effect. This drug class is likely the most efficacious for IBS with diarrhoea (recommendation: weak, quality of evidence: moderate to high).

- The non-absorbable antibiotic rifaximin is an efficacious second-line drug for IBS with diarrhoea in secondary care, although its effect on abdominal pain is limited. The drug is licensed for IBS with diarrhoea in the USA but is not available for this indication in many countries (recommendation: weak, quality of evidence: moderate).

- Linaclotide, a guanylate cyclase-C agonist, is an efficacious second-line drug for IBS with constipation in secondary care. It is likely to be the most efficacious secretagogue available for IBS with constipation, although diarrhoea is a common side effect (recommendation: strong, quality of evidence: high).

- Lubiprostone, a chloride channel activator, is an efficacious second-line drug for IBS with constipation in secondary care. This secretagogue is less likely to cause diarrhoea than others. However, patients should be warned that nausea is a frequent side effect (recommendation: strong, quality of evidence: moderate).

- Plecanatide, another guanylate cyclase-C agonist, is an efficacious second-line drug for IBS with constipation in secondary care. Diarrhoea is a common side effect and is no less likely than with linaclotide or tenapanor. Although
the drug is licensed for IBS with constipation in the USA, it is not yet available for this indication in many countries (recommendation: strong, quality of evidence: high).

- Tenapanor, a sodium-hydrogen exchange inhibitor, is an efficacious second-line drug for IBS with constipation in secondary care. Again, diarrhoea is a frequent side effect. Although the drug is licensed for IBS with constipation in the USA, it is not yet available for this indication in many countries (recommendation: strong, quality of evidence: high).

- Tegaserod, a 5-Hydroxytryptamine 4 receptor agonist, is an efficacious second-line drug for IBS with constipation in secondary care but is unavailable outside the USA. Diarrhoea is a common side effect (recommendation: strong, quality of evidence: moderate).

**Psychological therapies**

- IBS-specific cognitive behavioural therapy may be an efficacious treatment for global symptoms in IBS (recommendation: strong, quality of evidence: low).

- Gut-directed hypnotherapy may be an efficacious treatment for global symptoms in IBS (recommendation: strong, quality of evidence: low).

- Psychological therapies should be considered when symptoms have not improved after 12 months of drug treatment. Referral can be made at an earlier stage, if accessible locally, and based on patient preference (recommendation: strong, quality of evidence: low).

**Management of severe or refractory IBS**

- Severe or refractory IBS symptoms should prompt a review of the diagnosis, with consideration of further targeted investigation (recommendation: weak, evidence: very low).

- Severe or refractory IBS should be managed with an integrated multi-disciplinary approach (recommendation: weak, evidence: very low).

- Iatrogenic harms due to opioid prescribing, unnecessary surgery and unproven unregulated diagnostic or therapeutic approaches incentivised by financial or reputational gain should be avoided (recommendation: strong, evidence: very low).

- Use of combination gut-brain neuromodulators, termed augmentation, may be considered for more severe symptoms, with vigilance for risks of serotonin syndrome (recommendation: weak, evidence: very low).

**Research**

- Successful completion of large clinical trials will require pragmatic inclusion criteria, minimisation of the participant trial burden and effective recruitment strategies that reach into community settings. Virtual (remote access) trial approaches will reduce geographical exclusion.

- A priority-setting partnership would best discern valuable research questions.

- Some future research themes include, but are not limited to:
  - Characterisation of the illness to understand predictors (clinical, genetic, psychological and biological) of outcome and treatment response, determinants of refractory illness and burden of illness (particularly with respect to workplace productivity) by conducting large-scale epidemiological studies with extended observation.
  - Trials of novel treatments, including pharmacological, dietary and behavioural therapies, device-based treatments and faecal microbiota transplantation. There is also a need for development of visceral analgesics. Consideration should be given to stratifying randomised controlled trials by IBS severity and subtype, burden of extraintestinal symptoms and psychological comorbidity.
  - A better understanding of treatment combinations to uncover augmentation effects between therapies, and to assess the value of multidisciplinary approaches.
  - Modulation of pain and psychological responses using pharmacological (eg, serotonin norepinephrine reuptake inhibitors) or behavioural approaches (eg, cognitive behavioural therapy used earlier in the disease course or via digital provision), and comparison of cognitive behavioural therapy with gut-directed hypnotherapy.
  - Med-tech approaches (web-based, apps and devices) to behavioural modification.

**Patient summary**

These guidelines have been produced on behalf of the British Society of Gastroenterology (BSG) by a team of specialists, and with input from patients with irritable bowel syndrome (IBS). The guidelines are aimed at healthcare professionals who look after patients with IBS.

IBS is a common condition, which is caused by problems arising between the gut and the brain. It consists of symptoms like abdominal pain linked to changes in bowel frequency or appearance of stools, and often bloating. Problems in IBS have been found in the nervous system supplying the gut, often making it more sensitive. Psychological factors (including stress), certain foods and the micro-organisms (bugs) living in the gut can all play a role in triggering symptoms. Occasionally, it can start after a gut infection, or antibiotic use, but more often there is no clear origin.

Some patients with IBS learn to manage their symptoms themselves, by changing their lifestyle or diet, or managing stress differently. Others, however, will consult their general practitioner who can usually make the diagnosis based on the typical symptoms. General practitioners will carry out some blood tests, including one to rule out coeliac disease (an immune reaction to gluten) and, if diarrhoea is present, a stool test to rule out inflammation. If there are concerning symptoms, including bleeding from the back passage, substantial weight loss or anaemia, a strong family history of cancer, or the patient is older, then the general practitioner will refer to a hospital specialist for further tests. The specialist may request a camera test of the large bowel, known as a colonoscopy, or do extra tests to look for other causes of diarrhoea or constipation, especially if the patient’s symptoms are less typical of IBS.

Regular exercise, making some simple dietary changes, and adopting healthy eating patterns will help many patients. Some patients find reducing dietary fibre improves symptoms, while others may find that a soluble fibre supplement helps. Referral to a dietician can be helpful if these first-line approaches to diet do not help. Taking supplements of probiotics (often referred to as ‘friendly bacteria’) may also help, but these can be expensive.

Some patients may require different medications, depending on their main symptom. Some of these can be obtained over the counter, but others need to be prescribed by a doctor. This guideline has reviewed the evidence for which medications work, and the possible harms they may cause. We have only recommended medications with good evidence that they are effective and have recommended against tests or treatments where the evidence is that they do not help, are harmful or where there is not enough.
Evidence. Some medications have most of their effect on the gut itself, others work both at the level of the gut and the brain (called ‘neuromodulators’ as they help to reduce nerve sensitivity). Some drugs that have good evidence are unfortunately not available, or are too expensive, in some countries.

There is good evidence that psychological treatments directed against IBS symptoms, especially cognitive behavioural therapy (CBT), and hypnotherapy, are helpful for many patients’ symptoms, but unfortunately these are not always readily accessible. Work is being done to improve access to these.

Very severe symptoms that do not respond to some of the above treatments are rare. However, patients whose symptoms do not improve may be left feeling desperate, and therefore vulnerable to approaches which are not proven, expensive or high risk. It is recommended that patients in this position are supported by a multidisciplinary specialist team to help reduce harms, such as unwarranted tests or operations, or harmful drugs.

Although much progress has been made in understanding and treating IBS, there are still many things we do not know about the condition, and there are lots of active areas for research, and therapies that need to be explored. We hope this guideline will also help to highlight and prioritise these areas.

**INTRODUCTION**

**Aims**

Since the last BSG guideline on IBS was published in 2007, there has been a considerable amount of new evidence pertaining to the pathophysiology, diagnosis, investigation and management of the condition. Furthermore, the gold standard symptom-based diagnostic criteria for IBS, the Rome criteria, are now in their fourth iteration. The primary aim of this guideline, commissioned by the BSG, is to update the 2007 guideline, considering all these developments, but with a particular focus on treatment of the condition. The overarching intention is to provide a guideline that is practical to use and an authoritative framework for current, state-of-the art, evidence-based clinical practice.

**Methodology**

In line with the Appraisal of Guidelines for Research & Evaluation guideline development protocol, a diverse multidisciplinary working group of clinicians and academics was convened from across the interface of primary, secondary and tertiary care, as well as psychology and dietetics. To ensure a patient-centred approach at the outset, the proposal was reviewed by the BSG network, Guts UK, and by four patients with IBS who were invited to join the working group.

Each section lead performed a comprehensive literature search, except for the section dealing with treatment, which was informed by a systematic review of the literature, the methodology for which is reported within that section. Eligible studies were graded according to the Oxford Centre for Evidence Based Medicine. The Grading of Recommendations Assessment, Development and Evaluation system was used to evaluate the strength of the recommendations and the overall quality of evidence. Thereafter, all members of the working group reviewed and approved the entire guideline.

**Conflicts of interest**

All members of the working group were asked to complete conflicts of interest declarations. These are available as a supplementary online table.

**Scheduled review**

We would suggest these guidelines are reviewed and updated every 4 years.

**CLASSIFICATION AND DIAGNOSTIC CRITERIA**

In the absence of any biomarker being available for IBS, the condition is diagnosed using a positive approach, based on the clinical history. Symptom-based diagnostic criteria have been developed to facilitate this, according to a specific pattern of gastrointestinal symptoms reported by the patient, with recourse to limited investigations. These criteria were developed by the Rome Foundation, and the most recent iteration, Rome IV, were published in 2016 (table 1). These define IBS as the presence of abdominal pain, related to defaecation, associated with a change in stool frequency and/or stool form. Patients are subgrouped according to their predominant stool pattern into IBS with diarrhoea (IBS-D), IBS with constipation (IBS-C), IBS with mixed bowel habits (IBS-M) or IBS unclassified (IBS-U), to direct therapy. The presence of abdominal pain at the required frequency distinguishes IBS from the other functional bowel disorders, which consist of functional constipation, functional diarrhoea and functional abdominal bloating or distension. However, there is some degree of overlap and fluctuation between IBS and these other disorders. The Rome IV process also redefined IBS as a disorder of gut-brain interaction, in recognition of the complex interplay of biological, psychological, and social factors underpinning the condition.

The Rome IV criteria made some important changes, compared with their predecessor, Rome III. First, abdominal ‘discomfort’ was removed from the definition, as this was felt to be a vague term that was not understandable in some languages. Second, the minimum required frequency of abdominal pain was increased from at least 3 days per month, to at least 1 day per week. This change reflected the findings of a normative survey showing that adopting a higher threshold for the frequency of abdominal pain required to meet criteria for IBS would lead to fewer healthy people in the general population being misclassified as having IBS, and therefore risk being ‘medicalised’, and having to take drugs for the condition. This feature makes the Rome IV criteria potentially more specific than Rome III. Third, it was no longer necessary for abdominal pain to be relieved by defaecation. Instead, it should be ‘related to defaecation’, acknowledging that some patients with IBS report that their pain worsens following a bowel movement.

This more restrictive nature of the Rome IV criteria calls into question whether they should be used to diagnose IBS in clinical practice, and a more pragmatic definition of the symptoms that constitute IBS may be preferred. The National Institute for Health and Care Excellence (NICE) guideline for the management of IBS in primary care recommends a broader, more pragmatic, definition of IBS, focusing on abdominal pain or discomfort associated with altered stool frequency or stool form for at least 6 months, in the absence of alarm symptoms or signs, and acknowledging that coexistent bloating, lethargy, nausea, backache or bladder symptoms are common.

**Epidemiology**

Symptoms compatible with IBS are extremely common in the general population at any particular point in time, and experienced on a continuum, from what may be fleeting and part of normal health, to a disease process, requiring medical input. In the latter instance, IBS is chronic, with fluctuating symptoms, in the majority of patients. However, few epidemiological studies
have conducted follow-up beyond 12 months, and most drug trials take place over 12 weeks, meaning that factors predicting continuation or resolution of symptoms is unclear. The condition impacts on social functioning, quality of life, and ability to work, with one-in-four patients reporting sickness-related absences from work, and up to 80% presenteeism in the workplace. The annual direct and indirect costs related to IBS are estimated to be up to €8 billion in Europe, ¥123 billion in China, and in excess of US$10 billion in the USA.

Prior to the publication of the Rome IV criteria in 2016, 2 systematic reviews and meta-analyses quantified the global prevalence of IBS. The first of these, published in 2012, included data from 260,960 individuals across 81 different countries and calculated a pooled global prevalence of IBS of 11%, irrespective of definition used. Prevalence varied widely between countries, and according to the criteria used to define IBS, ranging from 1.1% in one Iranian study that used the Rome III criteria, to 43% in a study from Pakistan that used Rome II. The second systematic review and meta-analysis, from 2017 and conducted by the Rome Foundation, found similar variability in the prevalence of IBS, which ranged from 1.1% in France and Iran, to 35.5% in Mexico, and with a pooled global prevalence of 8.8%. In both meta-analyses, heterogeneity between studies was substantial, presumably relating to differences in methodology, demographic characteristics of participants, cultural issues or a combination of these factors.

Due to the uncertainty surrounding pooled estimates of global prevalence, and the apparent variation in prevalence between countries in separate studies, a subsequent Rome Foundation global survey has quantified the prevalence of IBS, among 73,000 adults in 33 different countries simultaneously, using both the Rome III and IV criteria. The worldwide prevalence of IBS was 4.1% using the Rome IV criteria, compared with 10.1% with Rome III. An update of the systematic review and meta-analysis from 2012 incorporating the results of this global survey demonstrated a pooled prevalence of IBS according to the Rome III criteria of 9.2%, in 53 studies recruiting 400,000 participants from 38 countries, compared with 3.8% using Rome IV, based on findings from 6 studies including over 80,000 individuals from 34 countries. With respect to sex, the prevalence of IBS was modestly, but significantly, higher in women than men in this meta-analysis (odds ratio (OR) 1.46; 95% CI 1.33 to 1.59) based on 30 studies using the Rome III criteria. The Rome Foundation global survey also reported a substantially higher pooled prevalence of IBS among women, compared with men, using the Rome IV criteria (OR 1.8; 95% CI 1.7 to 2.0). Prevalence of IBS decreased modestly with increasing age, irrespective of diagnostic criteria, in a prior meta-analysis, although this trend was not statistically significant. Similarly, in the Rome Foundation global survey, prevalence of both Rome III and Rome IV IBS decreased with age and was highest among adults aged 18–39 years.

The fall in prevalence in IBS that results from the changes made in moving from the Rome III to Rome IV criteria is noteworthy, reflecting the more restrictive nature of the latter. This has important clinical implications because, although as intended, the criteria are now more specific for diagnosing IBS, up to 50% of patients who believe they have IBS will no longer meet criteria for the condition. Instead, they will be diagnosed as having another functional bowel disorder, such as functional diarrhoea, functional constipation or functional abdominal bloating or distension. Moreover, there may be an impact on treatment trials in IBS, and the interpretation of results, because patient populations recruited using the Rome IV criteria will
differ from those recruited using Rome III, and may have more severe symptoms and higher degrees of psychological comorbidity. Moving from Rome III to Rome IV IBS may therefore reduce the likelihood of novel pharmacological therapies demonstrating efficacy in future randomised controlled trials (RCTs), due to the spectrum of symptom severity, or may mean that trials need to be considerably larger, and therefore more expensive to conduct, to show a beneficial effect.

**PATHOPHYSIOLOGY**

The pathophysiology of IBS is complex and remains poorly understood. Genetics, and epigenetic changes, infection and early adverse life events may predispose an individual to developing IBS, and chronic stress, psychological symptoms, negative beliefs about symptoms and illness and maladaptive coping mechanisms can increase the frequency and severity of symptoms. For some patients with IBS, psychological comorbidity or distress may be a consequence, rather than a cause, of the severity and frequency of symptoms experienced. IBS is a disorder of altered bidirectional communication between the gut and brain (via the gut-brain axis), and has a biopsychosocial aetiology. As a result, it has been re-termed a disorder of gut-brain interaction. An exhaustive discussion of the involved pathophysiological mechanisms is beyond the scope of this guideline, but the best accepted of these are summarised below.

**Central nervous system and autonomic nervous system modulation**

Symptoms are generated by interoceptive signals from the gut, and memories of such signals, and are modulated by emotional (anxiety, depression), cognitive (attention, beliefs and expectation) and motivational factors. Altered activation of brain regions responsible for cognitive processing and emotional and autonomic responses to visceral and somatic stimuli are seen in IBS, consistent with visceral hypersensitivity, hypervigilance and symptom-related anxiety. Some patients with IBS have compromised central inhibitory regulation of visceral and somatic stimuli. Modulating activity of the brain regions responsible for visceral pain using various therapies has been shown to improve IBS symptomatology.

The autonomic nervous system mediates communication between the gut and brain. In IBS, a reduction in parasympathetic activity and an increase in sympathetic nervous system activity is frequently observed. Reduced vagal tone may be caused by stress, and impacts on gut motility and sensitivity, and peripheral inflammation and gut permeability. Conversely, the vagus nerve may sense the gut microenvironment indirectly and transfer this information to the brain.

**Altered visceral perception**

Between 20% and 60% of patients with IBS have enhanced visceral perception to various physiological stimuli (e.g., mechanical or electrical). Hypersensitivity to mechanical distension of the gut is reported by more patients with IBS-D than IBS-C. However, studies do not distinguish between affective, cognitive and true peripheral, versus central, mechanisms of visceral hypersensitivity. A study conducted in separate patient cohorts from Sweden, Belgium and the USA reported that visceral sensitivity correlated positively with symptom severity, even after adjustment for the tendency to report symptoms or psychological comorbidity. Approximately 20% of patients with IBS are viscerally hyposensitive or insensitive to mechanical distension, more commonly those with IBS-C than IBS-D, with one study suggesting that the degree of insensitivity correlated with abdominal distension (ie, a true physical increase in abdominal girth).

**Transit and motility**

Colonic transit is abnormal in only 10%–20% of patients with IBS-C and IBS-M, and 25%–45% of patients with IBS-D. Similar observations are seen for oro-caecal transit. However, patients with normal transit can still have abnormal fasting and postprandial motility. Patients with IBS-C display reduced motility, fewer high amplitude propagating contractions of the colon and delayed transit, whereas those with IBS-D have increased motility, more high amplitude propagating contractions and accelerated transit. Colonic transit time correlates inversely with stool consistency and, to a lesser extent, with stool frequency. However, symptoms of abdominal pain, bloating and flatulence correlate poorly, or not at all, with colonic transit, whereas abdominal distension (the physical increase in abdominal girth, rather than the sensation of bloating) correlates with oro-caecal and colonic transit times, and inversely with stool consistency. High amplitude propagating contractions in patients with IBS-D are associated with abdominal pain. Changes in gastrointestinal motility may be influenced by alterations in serotonin (5-Hydroxytryptamine (5-HT)) metabolism, with high levels reported in patients with IBS-D, and low levels in IBS-C.

**Immune regulation, inflammation and epithelial permeability**

Low-grade mucosal inflammation may arise from a compromised epithelial barrier, dysbiosis or altered stress levels, and impaired epithelial barrier function from an aberrant stress and immune response, and/or dysbiosis. It can be linked to a previous episode of infectious gastroenteritis induced by bacteria, parasites or viruses, referred to as postinfection IBS (PI-IBS). Increased numbers of mast cells, particularly in the descending colon and rectosigmoid region, and in the small intestine, is the most consistent histological finding in IBS. Mast cell hyperplasia is more common in IBS-D and PI-IBS. The severity and frequency of abdominal pain correlates with the presence of activated mast cells in close proximity to nerve endings in the gut mucosa in some studies, but in others mast cell proliferation associates with a reduction, or no change, in visceral sensitivity. Interleukin-10 mRNA expression and protein levels are consistently reduced in the mucosa and/or peripheral circulation, in patients with IBS-D and PI-IBS, and associate with comorbid anxiety or depression. There is lack of consensus on whether numbers of T cells and levels of cytokines in the peripheral circulation of patients with IBS are abnormal.

Increased permeability in patients with PI-IBS and IBS-D correlates with visceral sensitivity, and symptom severity. However, findings in patients with IBS-C are inconsistent. The expression and levels of the tight junction protein zonula occludens are significantly reduced in IBS-D, and associated with mast cell activation and symptoms. Confocal laser endomicroscopy studies suggest exposure to certain food antigens can disrupt the epithelial barrier in approximately 50% of patients with IBS. Removal of the reacting antigen from the diet improved symptoms significantly.

**The microbiome**

Strong evidence supports a role for bacterial, viral or parasitic infections triggering IBS. Antibiotic usage may also associate with either the development, or improvement, of
IBS symptoms. Moreover, changes in the gut microbiome can modify gastrointestinal motility, visceral sensation, intestinal permeability, stool consistency and visceral sensitivity. 71 72 In a mouse model, bacterial infection led to an increase in intestinal permeability, which appeared to allow previously tolerated food antigens to activate a localised host immune response in the gastrointestinal tract, via IgE, leading to histamine release, altered motility and visceral hypersensitivity. 73 There is no conclusive evidence for a specific IBS gut microbiome profile. 74 75 However, an integrated longitudinal multi-omics analysis of the gut microbiome, metabolome, host epigenome and transcriptome, in the context of host symptoms and physiology in patients with IBS-D and IBS-C, identified subtype-specific and symptom-related variations in microbial composition and function. 76 It remains unclear whether such microbial changes are secondary and relate to other factors including diet, drugs, altered physiology, including gastrointestinal transit or gastrointestinal water content.

Genetics and epigenetics
Familial clustering of IBS may be attributed to both genetic and shared environmental factors. 77 78 In addition, numerous genetic single nucleotide polymorphisms have been described in association with symptom phenotypes, regulation of neurotransmission, barrier function, inflammatory mediators, ion channels and bile acid metabolism in IBS. 77 78 However, a meta-analysis of genes associated with inflammatory mediators found no significant associations for most genes assessed. 79 There is some evidence for epigenetic changes in IBS, including alterations in DNA methylation, and various miRNAs appear to be associated with increased visceral sensitivity and permeability. 80

PRESENTATION OF IBS, DIAGNOSIS AND MANAGEMENT IN PRIMARY CARE
Overview
Patients may have IBS-type symptoms for many years without presenting to medical care, often self-managing their symptoms without medical input, and some may never consult. Nevertheless, lower gastrointestinal symptoms frequently prompt people to present to primary care, 81 accounting for approximately 1 in 12 of all consultations. 82 Functional gastrointestinal disorders, such as IBS, are by far the most common diagnosis, but symptoms can be difficult to assess and the possibility of colorectal cancer or inflammatory bowel disease (IBD) may create diagnostic uncertainty for clinicians, and anxiety for patients. 83 General practitioners are the first point of contact and provide the diagnosis and medical care for most people with IBS. Management guidelines encourage general practitioners to make a positive diagnosis of IBS, based on symptoms, in the absence of alarm symptoms or signs that warrant referral to exclude colorectal cancer (box 1). 84 or abnormalities on simple investigations. 85 However, persistent abdominal bloating or distension in female patients should prompt consideration of CA-125 and pelvic ultrasound to exclude ovarian cancer. 85 General practitioners provide the majority of long-term medical care for people with IBS, referring only a minority of patients to specialist clinics. 86 Compared with hospital settings, general practitioners can, and should, aim to build a long-term relationship with patients, harnessing this to develop a shared understanding of their IBS in the context of their other medical conditions, concerns, priorities and impact on their lives. 87 88 This can assist in providing appropriate tailored education, advice and reassurance, shared decision-making and management plans, and be facilitated by an ongoing supportive doctor-patient relationship and prioritisation of continuity of care.

Doctor-patient communication and patient perspectives in primary care
Establishing an effective doctor-patient relationship and a shared understanding is key to the successful diagnosis and management of chronic conditions such as IBS. 89 90 Reports from patients with IBS confirm that they would like increased empathy, support and information about the nature of the condition from general practitioners, and options for symptom management. 87 They often feel their symptoms are dismissed or trivialised, describe the diagnostic process as confusing, or invasive, and the often-lengthy search for efficacious treatments as frustrating. 87 89 91–95 Patients often seek information and support from multiple sources, including internet web forums, 96 and may receive conflicting, or incorrect, advice. Clinicians should aim to gain a better understanding of patients’ ideas, concerns and expectations of diagnosis and management. Multiple factors influence both the patient’s decision to consult their doctor with IBS, and their ability and willingness to self-manage symptoms and engage with treatment. These factors include the impact on their own and their family’s lives, social and psychological factors, employment, comorbidities and health beliefs. All should be considered and acknowledged for successful diagnosis and management of IBS in primary care, and good doctor-patient communication generally.

Presentation of IBS to primary care
General practitioners must assess and manage undifferentiated disease, multiple comorbidities, health anxieties and hidden agendas in brief consultations. Multiple factors, described above, influence patients’ decisions to consult. Concerns about serious illness, advice or pressure from friends or relatives, life events and underlying health beliefs can all drive healthcare-seeking behaviour. Understanding reasons for presenting at a particular point in time, especially if symptoms have been present for many years, is important in determining the most appropriate management strategy.

Box 1 Lower gastrointestinal alarm symptoms or signs that are referral criteria for suspected colorectal cancer 84

<table>
<thead>
<tr>
<th>Definite referral criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Aged ≥40 years with unexplained weight loss and abdominal pain.</td>
</tr>
<tr>
<td>2. Aged ≥50 years with unexplained rectal bleeding.</td>
</tr>
<tr>
<td>3. Aged ≥60 years with:</td>
</tr>
<tr>
<td>a. Iron deficiency anaemia;</td>
</tr>
<tr>
<td>b. Change in bowel habit;</td>
</tr>
<tr>
<td>c. Weight loss;</td>
</tr>
<tr>
<td>d. Iron deficiency anaemia.</td>
</tr>
</tbody>
</table>

Probable referral criteria
1. Adults of any age with an abdominal or rectal mass.
2. Aged <50 years with rectal bleeding and any of the following unexplained symptoms or findings:
   a. Abdominal pain;
   b. Change in bowel habit;
   c. Weight loss;
   d. Iron deficiency anaemia.
General practitioners’ key skills, especially in relation to chronic disorders such as IBS, are to make a positive diagnosis, including providing a simple explanation of the pathophysiology underlying the symptoms, clarifying the patient’s main concerns and managing current symptoms in the wider context of the patient’s life. The doctor’s relationship with the patient, continuity of care, empathy, including acknowledgement of the impact of symptoms on daily life, a shared understanding of IBS and shared decision-making can assist in providing appropriate education, signposting to reputable online information or peer support, reassurance, advice and management options.

Diagnosis of IBS in primary care
The key to diagnosis starts with skilled, targeted history taking and examination, considering the patient’s medical history and life circumstances. The Rome diagnostic criteria are based on specific symptoms of a defined duration and frequency, which have been derived predominantly from secondary care patients, and are rarely used in primary care. Their applicability to clinical practice has been challenged as unnecessarily restrictive, and only a minority of people diagnosed with IBS in primary care fulfil them. This restrictive diagnostic approach to IBS may be unhelpful and overly complicated in this setting, where fundamentals of clinical management are common across all these functional gastrointestinal disorders. Applying rigid criteria potentially leaves many patients with troublesome impactful symptoms without a clear diagnosis, increasing uncertainty and leading to issues with providing appropriate advice and management options. The NICE guideline definition of IBS is therefore preferable.

Investigation in primary care
A positive diagnosis of IBS can be made on the basis of ongoing characteristic symptoms, after assessing for alarm symptoms or signs, and undertaking relevant blood test results, including full blood count (FBC), C reactive protein (CRP) or erythrocyte sedimentation rate (ESR), and serological tests for coeliac disease. The chance of identifying organic disease on the basis of checking FBC, CRP and ESR in suspected IBS is low, but the prevalence of abnormal serological testing for coeliac disease is almost three times higher in people with suspected IBS than people without symptoms of IBS, irrespective of predominant stool pattern. If all these blood tests are normal, other investigations should be minimised. Abdominal and digital rectal examination can help exclude other diagnoses, and may confirm the consistency of stool, including rectal impaction, or identify dyssynergic defaecation (paradoxical contraction on rectal examination during straining) or low rectal masses. An abdominal X-ray can be considered to rule out faecal loading if constipation is the predominant symptom.

The non-invasive marker of intestinal inflammation faecal calprotectin has enabled risk stratification to prioritise access to investigations to exclude IBD in patients with chronic diarrhoea, reducing unnecessary investigations and referrals from primary to secondary care. However, calprotectin is not specific to IBD and can be elevated in older age groups (age ≥45 years), obesity, infection, malignancy or by medications, such as proton pump inhibitors (PPIs) or non-steroidal anti-inflammatory drugs (NSAIDs). Local laboratory values vary but, generally, a faecal calprotectin of <100 μg/g can be considered normal, 100–249 μg/g is borderline and should be repeated, with subsequent referral if persistently elevated, and ≥250 μg/g requires urgent referral to secondary care to exclude IBD. Faecal occult blood or faecal immunochromatographic testing are not used routinely for assessing patients with possible IBS in primary care, although they are recommended in current guidelines for colorectal cancer screening. Local and national guidelines for colorectal and ovarian cancer screening should be followed, where indicated. Once a diagnosis of IBS has been made, the general practitioner should endeavour to follow-up the patient within the next 2 months to ensure symptoms are not getting progressively worse, which may be indicative of a more sinister underlying disease process.

When to refer patients to secondary care
Most patients with IBS are diagnosed and managed by general practitioners in community settings and are never referred to secondary care, even if they have ongoing troublesome symptoms. In a primary care study of patients with refractory IBS, only 10% had ever had a secondary care referral. Reasons for seeking a secondary care opinion include: uncertainty about the diagnosis or alarm symptoms or signs; ongoing refractory symptoms that have not improved despite lifestyle changes (including diet and trials of medication), necessitating initiation of therapies that are unavailable in primary care or patient request for a specialist opinion.

Recommendations
- Establishing an effective doctor-patient relationship and a shared understanding is key to the management of IBS. Such a relationship can lead to improved quality of life and symptoms, reduce healthcare visits and enhance adherence to treatment (recommendation: strong, quality of evidence: low).
- Patients with IBS would like increased empathy, support and information from clinicians about the nature of the condition, diagnosis and symptom management options (recommendation: strong, quality of evidence: low).
- The National Institute for Health and Care Excellence guideline definition of IBS (abdominal pain or discomfort, in association with altered bowel habit, for at least 6 months, in the absence of alarm symptoms or signs) is more pragmatic and may be more applicable to patients with IBS in primary care than diagnostic criteria derived from patients in secondary care, such as the Rome IV criteria (recommendation: weak, quality of evidence: low).
- All patients presenting with symptoms of IBS for the first time in primary care should have a full blood count, C reactive protein or erythrocyte sedimentation rate, coeliac serology and, in patients <45 years of age with diarrhoea, a faecal calprotectin to exclude inflammatory bowel disease. Local and national guidelines for colorectal and ovarian cancer screening should be followed, where indicated (recommendation: strong, quality of evidence: moderate).
- Clinicians should make a positive diagnosis of IBS based on symptoms, in the absence of alarm symptoms or signs, and abnormalities on simple blood and stool tests (recommendation: strong, quality of evidence: moderate).
- Referral to gastroenterology in secondary care is warranted where there is diagnostic doubt, in patients with symptoms that are severe, or refractory to first-line treatments, or...
where the individual patient requests a specialist opinion (recommendation: weak, quality of evidence: low).

**CLINICAL HISTORY AND INVESTIGATION IN SECONDARY CARE**

The first consultation in secondary care

IBS is one of the most common disorders that gastroenterologists deal with, accounting for at least 10% of consultations in the outpatient clinic. Patients presenting to secondary care often attend the consultation with the hope that the specialist can diagnose an organic disease that has been missed in primary care. This may be because a diagnosis of IBS is stigmatised, or considered, erroneously, as a purely psychological disorder, or due to unexpressed concerns of a missed sinister cause of their symptoms. These aspects should all be considered by the secondary care clinician when managing patient expectations and selecting appropriate investigations. It is equally important to build rapport and to build trust in the doctor-patient relationship in secondary care by adopting the principles of empathic listening to optimise the interaction. Evidence suggests that 2 minutes of active listening at the beginning of a consultation gives the patient the feeling of having been listened to, and therefore having confidence in subsequent decisions around their care. An empathic approach can improve quality of life and symptoms, reduce healthcare visits and enhance adherence to treatment. It is useful to screen for potential symptom triggers, including previous acute enteric infection, present in approximately 10% of people with IBS, antibiotics or psychological stress. This demonstrates to the patient that the clinician is interested in understanding their disorder, and helps the patient’s understanding of the possible underlying aetiology and validates the diagnosis.

It is important to start the consultation by asking when the patient’s symptoms started (figure 1). A detailed history should confirm presence of the cardinal symptoms of IBS. These include abdominal pain and altered bowel habit (abnormal stool frequency and/or consistency) and, in particular, the relationship between the two, remembering that the location of pain can be in the upper or lower abdomen. Importantly, the clinician needs to assess whether the patient recognises that there is a link between the pain and the alteration in bowel habit. Thus, pain can be relieved or exacerbated by defaecation, or associate temporally with changes in bowel habit (eg, the pain is present when the individual is more constipated or has worsening diarrhoea). Predominant stool pattern, on days when the patient’s stools are abnormal, should be assessed using the Bristol stool chart. Attention should also be paid to other gastrointestinal symptoms. The presence of bloating is not required to fulfill the Rome IV criteria but, if present, is highly suggestive of IBS, and is often accompanied by visible abdominal distension. Although the Rome IV criteria are the gold standard to define IBS for research purposes, they are probably overly restrictive for use, even in secondary care, and a pragmatic definition in line with

![Figure 1](http://gut.bmj.com/)

**Figure 1** Diagnostic algorithm detailing the approach to the positive diagnosis of IBS. If the initial faecal calprotectin level is abnormal (eg, ≥250 μg/g), the suspicion for IBD is high, proceed to colonoscopy; if the initial faecal calprotectin level is indeterminate according to local laboratory values (eg, 100–249 μg/g), repeat the test off non-steroidal anti-inflammatory drugs, proton pump inhibitors, etc, and refer for colonoscopy if the repeat test remains indeterminate or is abnormal. SeHCAT, 23-seleno-25-homotaurocholic acid.
that used in the NICE guideline, and outlined above, should be preferred. Coexistent early satiety, postprandial fullness, epigastric pain, nausea or heartburn are common, as functional dyspepsia and gastro-oesophageal reflux frequently overlap with IBS. Extraintestinal symptoms, such as back pain, bladder and gynaecological symptoms, and insomnia are frequent, as is the presence of other functional somatic disorders, such as fibromyalgia, tension headache or chronic fatigue. Common mental disorders, and somatoform-type behaviour, often coexist. A patient with more severe IBS may volunteer a history of abuse, or respond to a cue when told that ‘some people report abuse as a possible cause…’. It is, therefore, important to consider all these factors when assessing a patient with a possible diagnosis of IBS during the initial consultation, as they add diagnostic value, and predict the degree of functional limitation of the condition, reduction in quality of life and healthcare utilisation. This may prevent presentation to multiple other specialties, and avoid iatrogenic harm from unnecessary investigations. Objective evidence of weight loss is also important to assess and document. Other relevant items in the clinical history include previous surgical interventions, and a family history of gastrointestinal cancer, IBD, coeliac disease or IBS. Finally, attention should be taken to exclude gastrointestinal symptoms related to a change in diet, drugs that can alter gut motility, such as psychotropic agents or opioids or alcohol excess.

Investigations in secondary care

In a patient with normal investigations from primary care on referral, exhibiting typical symptoms, and in the absence of alarm symptoms or signs, or atypical features, the diagnosis of IBS is secure (figure 1). A validation study of the Rome IV criteria in secondary care demonstrated this was particularly the case for IBS-C and IBS-D. Patients meeting these criteria were 21 times more likely to have IBS-C than to not have IBS-C, and 11 times more likely to have IBS-M than to not have IBS-M after limited diagnostic workup. The clinician should, therefore, appear confident and, after clinical assessment is complete, communicate a positive diagnosis of IBS based on symptoms. In those with alarm symptoms or signs, urgent referral for colonoscopy or radiological evaluation of the colon is required, although the diagnostic performance of alarm symptoms or signs is modest, and up to 80% of patients with IBS in primary and secondary care will report at least one alarm symptom. In those with atypical features, such as nocturnal diarrhoea or abdominal pain, or features of obstructive defaecation, further limited investigation may be required to exclude important mimics. These include microscopic colitis or primary, or idiopathic, bile acid diarrhoea (BAD) in those with suspected IBS-D, and dyssynergic defaecation and other defaecatory disorders in those with suspected IBS-C. The yield of colonoscopy in patients with IBS is extremely low, and there is no evidence of reassurance being derived by patients from a normal examination. However, colonoscopy to exclude microscopic colitis should be considered in patients with diarrhoea. Factors that should alert the clinician to the possibility of microscopic colitis include female sex, age ≥50 years, coexistent autoimmune disease, nocturnal or severe, watery, diarrhoea, duration of diarrhoea <12 months, weight loss or use of potential precipitating drugs including NSAIDs, PPIs, selective serotonin reuptake inhibitors (SSRIs) or statins. In primary BAD, bile acids enter the colon, enhancing mucosal permeability, inducing water and electrolyte secretion, and accelerating colonic transit. The condition is diagnosed via 23-seleno-25-homotaurchoholic acid (SeHCAT) scanning, although this may be unavailable in some countries. A serum 7α-hydroxy-4-cholesten-3-one is a reasonable alternative. The current BSG guideline for the investigation of chronic diarrhoea does not recommend a therapeutic trial of a bile acid sequestrant as a diagnostic test for BAD, because a lack of response does not exclude the condition. Symptoms of BAD can mimic IBS-D, with between one-in-three and one-in-four patients with suspected IBS-D having an abnormal SeHCAT retention, and response rates to a bile acid sequestrant are higher at retention of <10% or <5%. Predictors of primary BAD are lacking, other than higher body mass index, but if nocturnal or severe diarrhoea is present the diagnosis should be considered. BAD should also be suspected in patients with symptoms suggestive of IBS-D with prior cholecystectomy.

Some investigators have reported a high prevalence of exocrine pancreatic insufficiency (EPI) in patients with suspected IBS, although other studies have not confirmed this. The current BSG guideline for the investigation of chronic diarrhoea only recommends screening patients for EPI, via faecal elastase, if features consistent with fat malabsorption are present. Similarly, testing patients with suspected IBS-D for EPI is not recommended, unless steatorrhoea is reported. Finally, there is no role for hydrogen breath testing to exclude lactose intolerance or small intestinal bacterial overgrowth in patients with IBS, particularly as these tests may be falsely positive in patients with IBS, due to rapid transit. Studies using small intestinal aspiration, considered the gold standard for diagnosing small intestinal bacterial overgrowth, have not demonstrated an increased prevalence of the condition in suspected IBS, and the lactulose breath test correlates poorly with small intestinal aspiration. In addition, despite this being the rationale for use of non-absorbable antibiotics in IBS, a positive breath test result does not predict response to treatment. Similarly, variants in the sucrase-isomaltase gene have been reported to be associated with an increased risk of IBS, and some investigators have reported evidence of sucrase-isomaltase deficiency on small intestinal biopsy in patients with suspected IBS, but at present there is insufficient evidence for consideration of routine testing.

Communicating a positive diagnosis and management plan in secondary care

A diagnosis of IBS needs to be communicated clearly to the patient using simple words and explanations. There is evidence that patient education about the condition can lead to an improvement in symptoms. It should be underlined that IBS is a chronic disorder, with recurrent fluctuating symptoms...
triggered by stress, intercurrent illnesses, drugs and often the act of eating. IBS is not associated with an increased risk of cancer or mortality, but affects quality of life to the same degree as organic gastrointestinal diseases, such as IBD. The main pathophysiological aspect is related to visceral hypersensitivity, which is also the principal target of many current treatments. Therefore, explaining IBS as a disorder of gut-brain interaction, together with a simple account of the gut-brain axis and how this is impacted by diet, stress, cognitive, behavioural and emotional responses to symptoms and postinfective changes is important. Such an approach may improve patient understanding and acceptance of a diagnosis of IBS, and engagement with a shared management plan to include an explanation of the mechanisms of action, potential side effects and rationale for the use of drugs or psychological and dietary therapies within the context of the gut-brain axis.

Recommendations

► There is no role for colonoscopy in IBS, other than in those with alarm symptoms or signs, or those with symptoms suggestive of IBS with diarrhoea who have atypical features and/or relevant risk factors that increase the likelihood of them having microscopic colitis (female sex, age ≥50 years, coexistent autoimmune disease, nocturnal or severe, watery, diarrhoea, duration of diarrhoea <12 months, weight loss or use of potential precipitating drugs including non-steroidal anti-inflammatory drugs, proton pump inhibitors, etc) (recommendation: strong, quality of evidence: moderate).

► In those with symptoms suggestive of IBS with diarrhoea, but with atypical features such as nocturnal diarrhoea, or a prior cholecystectomy, 23-seleno-25-homotaurocholic acid scanning or serum 7α-hydroxy-4-cholesten-3-one should be considered to exclude bile acid diarrhoea (recommendation: strong, quality of evidence: low).

► In patients with IBS and coexisting symptoms suggestive of a defaecatory disorder or faecal incontinence, anorectal physiology tests can be considered, where available, to select those who might benefit from biofeedback (recommendation: weak, quality of evidence: low).

► There is no role for testing for exocrine pancreatic insufficiency, or for hydrogen breath testing to rule out small intestinal bacterial overgrowth or carbohydrate intolerance, in patients with typical IBS symptoms (recommendation: strong, quality of evidence: weak).

► The diagnosis of IBS, its underlying pathophysiology and the natural history of the condition, including common symptom triggers, should be explained to the patient. This should introduce the concept of IBS as a disorder of gut-brain interaction, together with a simple account of the gut-brain axis and how this is impacted by diet, stress, cognitive, behavioural and emotional responses to symptoms, and postinfective changes (recommendation: strong, quality of evidence: weak).

**TREATMENT OF IBS**

**General overview**

The treatment of IBS is generally directed towards the predominant symptom, or symptoms, experienced by the patient. All patients should be advised of the potential benefits of regular exercise, as there is some evidence from RCTs that this can be beneficial, particularly for constipation, with beneficial effects still apparent at 5 years in one trial. Otherwise, treatment should commence with dietary therapies or first-line drugs, according to patient choice, with second-line drugs reserved for those whose symptoms do not improve with these measures, due to a combination of the potential side effects, as well as the costs, of some of these agents to the health service. Most second-line drugs are only available in secondary care. Ideally, the efficacy of selected treatments should be reviewed at 3 months, and discontinued if no response, with escalation to the next available therapy (figure 2). Currently, psychological therapies are reserved for patients whose symptoms are refractory to drugs, although more research is required to explore the efficacy of earlier use, and it may be worth mentioning them earlier on so that patients have the option to consider them, and so that they are not viewed as a last resort. There should be a realistic discussion concerning the limitations of all available treatments for IBS to manage expectations. It is important to stress that cure is unlikely, but substantial improvement in symptoms, social functioning and quality of life is achievable. The final decision regarding treatment choices should be made by the patient, with advice and support from the clinician.

Recommendations

► All patients with IBS should be advised to take regular exercise (recommendation: strong, quality of evidence: weak).

**Methodology for systematic reviews of IBS therapy**

To inform this guideline, we updated a series of systematic reviews and trial-based or network meta-analyses conducted by some of the authors. The aim was to assess the efficacy of dietary modifications and therapies, unlicensed, as well as licensed, pharmacological therapies, and psychological therapies in IBS. We considered RCTs comparing pharmacological therapies with placebo, psychological therapies with either no treatment or standard/usual care or dietary therapies with standard dietary advice, habitual diet or a sham dietary therapy. Cross-over trials were eligible for inclusion, provided extractable data were available at the end of the first treatment period, prior to cross-over. Studies recruited adults from primary, secondary or tertiary care with IBS symptoms diagnosed by any criteria (including clinical impression). Trials had to assess the effect of treatment in terms of either improvement of IBS symptoms, or improvement of abdominal pain, as a dichotomous assessment. It is important to point out that most RCTs of first-line treatments, as well as gut-brain neuromodulators and psychological therapies, used less rigorous end points to judge treatment efficacy, such as improvement in, or satisfactory relief of, global symptoms or abdominal pain. Trials of novel second-line drugs, on the other hand, tend to use Food and Drug Administration (FDA)-approved end points to judge efficacy, consisting of a ≥30% improvement in abdominal pain, an increase in the number of complete spontaneous bowel movements (CSBM)s per week in IBS-C, or a reduction in the number of days with stools of loose consistency in IBS-D, and composites thereof.

We considered the following treatments: soluble or insoluble fibre, a diet low in fermentable oligosaccharides, disaccharides and monosaccharides and polyols (FODMAPs), a gluten-free diet, probiotics, antidiarrhoeals, antispasmodic drugs (including peppermint oil), laxatives, gut-brain neuromodulators (tricyclic antidepressants (TCAs) and SSRIs, previously termed antidepressant drugs), eluxadoline, 5-HT₄ receptor antagonists, antibiotics, secretagogues, 5-HT₄ receptor agonists or psychological therapies (including gut-directed hypnotherapy) (online supplemental table 1). As this was an update of prior meta-analyses, we searched MEDLINE, EMBASE, EMBASE Classic and the
Cochrane central register of controlled trials between January 2017 and September 2020. The search strategy is provided in the online supplemental file 1. No restrictions were applied regarding language of publication. We conducted a recursive search of the bibliography of eligible articles. The lead reviewer (ACF) screened titles and trial abstracts that had been identified by the search strategy for articles that could possibly be eligible for the review. The lead reviewer (ACF) then screened the selected trials to confirm eligibility, using predesigned eligibility forms. A second reviewer (CJB), masked to the initial assessment, also evaluated all identified trials for eligibility. We resolved discrepancies by discussion, with a consensus view taken, and used the kappa statistic to measure the degree of agreement for judging study eligibility.

The literature search identified 4111 citations, of which 46 appeared to be relevant, and 17 were eligible and were incorporated into this guideline. Agreement between reviewers for study eligibility was excellent (kappa statistic=0.81). Of these 14 studies, 2 compared linaclotide with placebo, and were used to update a previous network meta-analysis, and 4 were RCTs of a low FODMAP diet, and again were used to update a prior trial-based meta-analysis. The remaining 3 RCTs were an 8-week trial of bimodal release ondansetron in IBS-D, and 2 phase II trials of minesapride, a novel 5-HT4 receptor agonist. The results of these latter 3 trials are discussed briefly below. Recommendations for all other treatments are, therefore, made based on the results of existing trial-based and network meta-analyses.

All data for newly identified RCTs were extracted independently by two investigators (ACF and CJB) on to a Microsoft Excel spreadsheet (XP professional edition; Microsoft, Redmond, Washington, USA). We resolved disagreements between investigators by discussion. We extracted data as intention-to-treat analyses, with all dropouts assumed to be treatment failures, wherever trial reporting allowed this. We incorporated data from newly identified trials into existing trial-based and network meta-analyses. As we examined binary outcomes (global IBS symptoms or abdominal pain improved or not improved), we expressed the impact of each intervention as a relative risk (RR) of global IBS symptoms or abdominal pain not improving, together with 95% CIs, where if the RR is <1 and the 95% CI does not cross 1, there is a significant benefit of the intervention over the control. This approach is the most stable, compared with RR of improvement, or using the OR, for some meta-analyses.

We used Review Manager V.5.4.1 (RevMan for Windows 2020, the Nordic Cochrane Centre, Copenhagen, Denmark) for updates to trial-based meta-analyses. We conducted updated network meta-analyses using the frequentist model, with the statistical package ‘netmeta’ (V0.9–0, https://cran.r-project.org/web/packages/netmeta/index.html) in R (V4.0.2). Network meta-analysis usually gives a more precise estimate, compared with results from standard, trial-based meta-analysis. It can
also rank treatments to inform clinical decisions, according to their P-score, which is a value between 0 and 1, with higher scores indicating a greater probability of a treatment being ranked as best. For both trial-based and network meta-analyses, we pooled data using a random effects model, to give a more conservative estimate of the efficacy of individual therapies, and assessed heterogeneity using the I² statistic, which ranges from 0% to 100%, with 0% representing no observed heterogeneity, and larger values indicating increasing heterogeneity. A value ≤50% was chosen to represent low levels of heterogeneity.

**Fibre and dietary therapies**

Over 80% of individuals with IBS report food-related symptoms, especially to fermentable carbohydrates and fats. Patients reporting adverse food reactions experience more severe gastrointestinal symptoms, associated subjective health complaints of musculoskeletal pain and chronic fatigue and reduced quality of life, compared with those without food sensitivities. Hence, most patients with IBS are keen to explore dietary options, with over 60% wanting to know what food(s) they should avoid, and up to 70% having modified their diet. There are multiple mechanisms by which food may trigger symptoms in IBS, including primary effects (eg, osmotic, chemical, immunological, mechanical or neuroendocrine) and secondary effects (eg, fermentation by-products, alterations in intraluminal pH or effects on the gut microbiome).

Patients may seek to undertake dietary manipulations based on tests that suggest potential food intolerances. A prior RCT, comprising 150 patients with IBS and positive IgG antibodies to food, found a significant improvement in symptoms in those allocated to a true-exclusion diet, compared with a sham-exclusion diet. However, the effect was modest and there are concerns regarding the poor specificity and applicability of IgG antibody testing. For example, IgG antibodies to yeast were reported in 87% of patients yet are rarely responsible for symptoms following dietary challenges. Hence, food elimination diets based on IgG antibodies are not recommended. Although some studies have identified potential food intolerances via leucocyte antigen testing of peripheral blood samples or real-time confocal laser endomicroscopy, this requires further corroboration.

In clinical practice, the last decade has seen a growing interest in the use of three diets for IBS, which are traditional dietary advice, a low FODMAP diet or a gluten-free diet. Of these, traditional dietary advice is considered as first-line, and is based on guidance produced by NICE and the British Dietetic Association (BDA). Its principles, which do not require formal dietetic input, include adopting healthy eating patterns, such as regular meals, maintaining adequate nutrition, limiting alcohol and caffeine intake, adjusting fibre intake, and reducing consumption of fatty and spicy foods. However, the evidence for this is based on a combination of clinical experience and the potential mechanisms by which these foods may induce gastrointestinal symptoms in IBS, rather than evidence from RCTs of this approach versus a control treatment. With regard to fibre, a systematic review and meta-analysis of 15 RCTs, comprising 946 patients, demonstrated its benefit in IBS (RR of symptoms persisting=0.87; 95% CI 0.80 to 0.94) (online supplemental figure 1). However, this effect was limited to soluble fibre, such as ispaghula (RR 0.83; 95% CI 0.73 to 0.94), but not insoluble fibre, like wheat bran, which may exacerbate abdominal pain and bloating. It is generally advised to start with low doses of soluble fibre (3–4 g daily) and build up gradually, as tolerated, to a total dosage of 20–30 g/day, as it increases colonic water content and volume, which may aggravate abdominal pain and bloating.

A low FODMAP diet is recommended as a second-line diet for IBS. FODMAPS are short-chain fermentable carbohydrates that are found in a variety of fruits, vegetables, dairy products, artificial sweeteners and wheat. They increase small intestinal water volume and colonic gas production and, in those with visceral hypersensitivity, induce gastrointestinal symptoms. They may also trigger bowel symptoms as they produce short chain fatty acids, which lower colonic pH. Hence, the benefits of adopting a low FODMAP diet in IBS seem physiologically plausible and several RCTs have evaluated its efficacy in IBS. The update to the prior systematic review and meta-analysis used to inform this guideline, identified 11 trials comparing a low FODMAP diet with various dietary control interventions, including habitual diet, a high FODMAP diet, traditional dietary advice as recommended by NICE and the BDA or a sham diet, in 658 participants. A low FODMAP diet was associated with a reduction in the risk of remaining symptomatic, compared with all control interventions (RR 0.71; 95% CI 0.61 to 0.83) (online supplemental figure 2). However, as reported in the prior meta-analysis, the quality of evidence from these trials was very low, due to small sample sizes, difficulties in blinding and heterogeneity between studies. The latter has mainly been attributed to the various control interventions used. Interestingly, those studies that compared the low FODMAP diet with traditional dietary advice from NICE and the BDA had the least heterogeneity, but also the least magnitude of effect (RR 0.82; 95% CI 0.67 to 1.01), suggesting that the 50%–70% symptomatic benefit reported for a low FODMAP diet in some studies may have been overestimated. Moreover, RCTs have focused solely on the initial ‘elimination’ phase of the low FODMAP diet, which lasts between 4 and 6 weeks, not the subsequent reintroduction and long-term ‘personalisation’ phase. The effect of FODMAP reintroduction to tolerance on IBS symptoms is therefore unclear, although there have been open-label studies reporting the long-term efficacy of an adapted low FODMAP diet ranges somewhere between 50% and 60%.

Finally, some patients with IBS report symptomatic benefit from a gluten-free diet despite no objective evidence of coeliac disease. The prior systematic review and meta-analysis identified only 2 RCTs comprising 111 participants and noted that although a gluten-free diet was associated with a reduction in global symptoms compared with a control diet, this was not statistically significant (RR 0.42; 95% CI 0.11 to 1.55). There is, therefore, insufficient evidence to recommend a gluten-free diet routinely in IBS, although given its widespread popularity further RCTs are needed. It has also been suggested that the clinical benefit reported with a gluten-free diet is, in the main, not due to the removal of gluten per se, but rather a reduction in dietary fructan content, which is a FODMAP, resulting from wheat exclusion. Future trials comparing a gluten-free diet head-to-head with a low FODMAP diet with regard to efficacy, convenience, cost and acceptability, may better inform patient choice.

Issues with following a low FODMAP diet, as opposed to traditional dietary advice, include the need for a specialist dietitian to implement it, followed by close monitoring to avoid nutritional deficiencies or the development of overly restrictive eating habits. The latter emphasises the importance of screening out patients at high risk for such behaviour prior to recommending such diets. This can be achieved using...
simple eating disorder questionnaires (eg, SCOFF), applying these carefully and with empathy, to identify those with high levels of psychological distress. Moreover, a low FODMAP diet may induce detrimental changes to the gut microbiota, with reductions in Bifidobacteria and total bacterial count, although the long-term consequences of this are unknown. Future studies should aim to identify actionable biomarkers that might predict response to a given dietary intervention. Preliminary data suggest that response to a low FODMAP diet may be predicted from baseline faecal bacterial profile and metabolomic activity, while a gluten-free diet may benefit those with serum antigliadin antibodies.

Reasonable to advise patients wishing to try probiotics to take them for up to 12 weeks, and to discontinue them if there is no improvement in symptoms (recommendation: weak, quality of evidence: very low).

Reasonations

► First-line dietary advice should be offered to all patients with IBS (recommendation: strong, quality of evidence: weak).

► Food elimination diets based on IgG antibodies are not recommended in patients with IBS (recommendation: strong, quality of evidence: moderate).

► Soluble fibre, such as ispaghula, is an effective treatment for global symptoms and abdominal pain in IBS, but insoluble fibre (eg, wheat bran) should be avoided as it may exacerbate symptoms. Soluble fibre should be commenced at a low dose (3–4 g/day) and built up gradually to avoid bloating (recommendation: strong, quality of evidence: moderate).

► A diet low in fermentable oligosaccharides, disaccharides and monosaccharides and polyols, as a second-line dietary therapy, is an effective treatment for global symptoms and abdominal pain in IBS, but its implementation should be supervised by a trained dietitian and fermentable oligosaccharides, disaccharides and monosaccharides and polyols should be reintroduced according to tolerance (recommendation: weak, quality of evidence very low).

► A gluten-free diet is not recommended in IBS (recommendation: weak, quality of evidence very low).

Probiotics

The faecal microbiome of patients with IBS may differ significantly from that of healthy individuals. The theory that this might, in part, be involved in pathophysiology has led to interest in whether probiotics, which are live or attenuated microorganisms that may have beneficial effects in humans, can be used to alter the microbiome, improving symptoms. We updated a prior meta-analysis of 37 RCTs, incorporating data from 8 new trials and randomising 6352 patients. Subgroup analyses according to type of probiotic used (where more than one trial of a particular group of probiotics was conducted) demonstrated significant effects on global symptoms or abdominal pain for combinations of probiotics (RR 0.79; 95% CI 0.70 to 0.89), Lactobacillus (RR 0.75; 95% CI 0.60 to 0.94), Bifidobacterium (RR 0.80; 95% CI 0.70 to 0.91) and Escherichia (RR 0.86; 95% CI 0.79 to 0.93) (online supplemental figure 3). Adverse event rates were similar in the probiotic and placebo arms. Variations in study design, strain and species of probiotic used, and heterogeneity between studies make it difficult to give specific recommendations. However, it is reasonable to advise patients wishing to try probiotics to take them for up to 12 weeks, and to discontinue treatment if there is no improvement in symptoms.

Recommendations

► Probiotics, as a group, may be an effective treatment for global symptoms and abdominal pain in IBS, but it is not possible to recommend a specific species or strain. It is reasonable to advise patients wishing to try probiotics to take them for up to 12 weeks, and to discontinue them if there is no improvement in symptoms (recommendation: weak, quality of evidence: very low).

Drugs used first line for IBS

Loperamide is a synthetic μ-opioid agonist that reduces myenteric plexus activity, thereby increasing intestinal transit time and enhancing water reabsorption. A prior systematic review identified only 2 RCTs of loperamide in IBS-D and IBS-M containing 42 patients. Although the drug improved stool frequency and consistency, it had no effect on global symptoms (RR 0.44; 95% CI 0.14 to 1.42). The incidence of adverse events with loperamide was similar to placebo in these trials. However, in clinical practice, abdominal pain, bloating, nausea and constipation are common side effects, and may limit tolerability. Titrating the dose carefully may improve tolerability.

Antispasmodics are among the most frequently used over-the-counter treatments for IBS, and can be divided, broadly, into antimuscarinics and smooth muscle relaxants. Antimuscarinics, including dicyclomine, propantheline, otilonium bromide and hyoscine butylbromide reduce intestinal motility, whereas alverine and mebeverine are direct-acting intestinal smooth muscle relaxants. The proposed mechanism of action of these agents is based on the assumption that some IBS symptoms are a result of gastrointestinal spasm and dysmotility, which antispasmodics ameliorate. A prior meta-analysis identified 26 RCTs, containing 2811 patients, which compared 13 different antispasmodics with placebo. Despite significant heterogeneity between trials, presumably driven by differences in antispasmodics studied, patient selection and study design, fewer patients treated with antispasmodics had persistent global symptoms or abdominal pain (RR 0.65; 95% CI 0.56 to 0.76) (online supplemental figure 4). However, these findings should be interpreted with caution, given heterogeneity between trial results and the varying end points studied. In addition, most trials recruited unselected patients with IBS, so whether the proposed reduction in gastrointestinal motility with antispasmodics improves diarrhoea is unclear. Access to some of these drugs is limited, although hyoscine butylbromide is available widely; pooled results from 3 RCTs, containing 426 patients, demonstrated efficacy (RR 0.63; 95% CI 0.51 to 0.78) (online supplemental figure 4). In contrast, in this meta-analysis, neither alverine nor mebeverine demonstrated benefit over placebo. The overall rates of adverse events were significantly higher with antispasmodics compared with placebo; most notably dry mouth, visual disturbance and dizziness.

Peppermint oil is another popular over-the-counter remedy for IBS. Although not completely understood, its putative antispasmodic action is via L-menthol’s blockade of calcium channels. A meta-analysis of 8 RCTs, which included 823 patients, has evaluated its efficacy. For global symptoms or abdominal pain, peppermint oil was more efficacious than placebo (RR 0.58; 95% CI 0.34 to 0.98) (online supplemental figure 5). It should be stressed that these trials involved specific formulations of peppermint oil. Their results, therefore, cannot be extrapolated to other formulations and, in the largest trial to date included in this meta-analysis, which used two formulations of variable release peppermint oil (small bowel vs ileocolonic) there was no benefit over placebo for the primary end point. In addition, low study quality, the lack of consistent use of the Rome criteria to define IBS and heterogeneity between RCTs limit confidence in the data. There is also a lack of information as to which...
IBS subtype would benefit most. Overall, adverse events with peppermint oil were no more common than placebo, although patients can report gastro-oesophageal reflux symptoms due to its effects on the lower oesophageal sphincter. Comparison of peppermint oil and antispasmodics with other unlicensed or ‘traditional’ treatments for IBS, including ispaghula and gut-brain neuromodulators, in a network meta-analysis suggested that, for global symptoms, peppermint oil was ranked first and antispasmodics third, with both superior to placebo (online supplemental figure 6). In terms of effect on abdominal pain, antispasmodics ranked second, with peppermint oil third (online supplemental figure 7). Again, both were significantly more efficacious than placebo.

Current NICE guidance for the management of IBS suggests that patients with IBS-C can be treated with laxatives, advising dose titration according to symptoms. Although both stimulant and osmotic laxatives are efficacious in the treatment of chronic idiopathic constipation, only the latter have been evaluated in 2 RCTs of polyethylene glycol, recruiting 181 patients with IBS-C. In one trial, there was no significant effect on either abdominal pain or number of bowel movements, and in the second the number of bowel movements increased significantly, but with no improvement in abdominal pain. Polyethylene glycol was generally well-tolerated with abdominal pain the most frequent adverse event. The long-term efficacy of osmotic laxatives in IBS-C is unknown, as both trials were of only 4 weeks duration.

**Recommendations**

- Loperamide may be an effective treatment for diarrhoea in IBS. However, abdominal pain, bloating, nausea and constipation are common, and may limit tolerability. Titrating the dose carefully may avoid this (recommendation: strong; quality of evidence: very low).

- Certain antispasmodics may be an effective treatment for global symptoms and abdominal pain in IBS. Dry mouth, visual disturbance and dizziness are common side effects (recommendation: weak, quality of evidence: very low).

- Peppermint oil may be an effective treatment for global symptoms and abdominal pain in IBS. Gastro-oesophageal reflux is a common side effect (recommendation: weak, quality of evidence: very low).

- Polyethylene glycol may be an effective treatment for constipation in IBS. Abdominal pain is a common side effect (recommendation: weak; quality of evidence: very low).

**Gut-brain neuromodulators**

Dysfunction within the bidirectional gut-brain axis is considered to play an important role in the genesis and maintenance of symptoms in IBS. Although IBS is often considered a functional gastrointestinal disorder, these conditions have, therefore, been re-termed as disorders of gut-brain interaction. Patients with IBS often have comorbid anxiety and depression, and these are also risk factors for the subsequent development of IBS in healthy people. This, together with their peripheral effects on gastrointestinal function, is part of the rationale for the use of gut-brain neuromodulators, such as TCAs and SSRIs. In a meta-analysis of 12 RCTs of TCAs, recruiting 787 patients, these drugs were superior to placebo for global symptoms or abdominal pain (RR 0.65; 95% CI 0.53 to 0.77) (online supplemental figure 8), and for abdominal pain alone (RR 0.59; 95% CI 0.42 to 0.83) (online supplemental figure 9). SSRIs were also more efficacious for global symptoms or abdominal pain (RR 0.68; 95% CI 0.51 to 0.91) (online supplemental figure 8), but not abdominal pain alone (online supplemental figure 9), and there was significant heterogeneity among the 7 trials, which contained only 356 patients. Adverse event rates were significantly higher among patients treated with TCAs or SSRIs, with drowsiness and dry mouth the most common. The effect of these drugs on stool pattern is less clear, as very few trials restricted their recruitment to a particular subgroup of patients.

Other gut-brain neuromodulators include serotonin norepinephrine reuptake inhibitors (SNRIs), such as duloxetine, or agents acting on the calcium channel α2δ ligand, including pregabalin. There have been no RCTs of SNRIs in IBS, although there is evidence from case series that duloxetine may improve symptoms and quality of life, and there is good evidence for use of SNRIs in other chronic painful disorders, such as fibromyalgia and low back pain. Pregabalin improved visceral hypersensitivity in one small trial, and in a recent RCT recruiting 85 patients with IBS, 12 weeks of pregabalin 225 mg twice daily led to significant improvements in global symptoms, abdominal pain, diarrhoea and bloating versus placebo.

Blurred vision, dizziness and altered sensation were more common with pregabalin. However, more RCTs are needed, and pregabalin is classed as a controlled drug in some countries. In a network meta-analysis evaluating relative efficacy of gut-brain modulators with other unlicensed or ‘traditional’ treatments, TCAs were ranked second and first for their effect on global symptoms and abdominal pain respectively, and were more efficacious than placebo (online supplemental figures 6 and 7). In contrast, SSRIs were ranked fifth and fourth for global symptoms and abdominal pain, respectively, and pregabalin was ranked sixth for global symptoms, with no benefit of either over placebo in these trials.

It is reasonable to consider using TCAs second line to treat global symptoms or abdominal pain or SSRIs second line to treat global symptoms, or if there is coexistent anxiety. They can be offered by general practitioners, depending on familiarity of use and expertise. The rationale for the use of gut-brain neuromodulators, as well as their side-effect profile, needs to be explained carefully to the patient, within the context of IBS as a disorder of gut-brain interaction. It should be reinforced that these drugs are being used at low doses for their pain modulatory properties and peripheral effects on gastrointestinal function, rather than at a dose that is used to treat common mental disorders. TCAs should be taken in the evening, before bedtime, due to their sedating effects, and may also improve sleep patterns. The patient should be counselled that these drugs take some time to have any benefit and that side effects, such as drowsiness, tend to ameliorate after the first 1 or 2 weeks of treatment. They should be commenced at a low dose (eg, 10 mg of amitriptyline once a day) and titrated relatively slowly in 10 mg increments, to a maximum of 30–50 mg once a day, with follow-up to assess efficacy and tolerability. If beneficial, the drugs are likely to be continued for a minimum of 6–12 months and, in some cases, this may be even longer-term.

**Recommendations**

- Tricyclic antidepressants used as gut-brain neuromodulators are an effective second-line drug for global symptoms and abdominal pain in IBS. They can be initiated in primary or secondary care, but careful explanation as to the rationale for their use is required, and patients should be counselled about their side-effect profile. They should be commenced at a low dose (eg, 10 mg amitriptyline once a day) and titrated up to a maximum dose of 150 mg daily.
slowly to a maximum of 30–50 mg once a day (recommendation: strong, quality of evidence: moderate).

- Selective serotonin reuptake inhibitors used as gut-brain neuromodulators may be an effective second-line drug for global symptoms in IBS. As with tricyclic antidepressants, they can be initiated in primary or secondary care, but careful explanation as to the rationale for their use is required, and patients should be counselled about their side-effect profile (recommendation: weak, quality of evidence: low).

**Drugs used second line for the treatment of IBS-D**

For patients with IBS-D who do not experience symptom improvement with antidiarrhoeals, several licensed therapies are available in secondary care. Eluxadoline is a μ-opioid and κ-opioid receptor agonist and δ-opioid receptor antagonist licensed for IBS-D. The drug slows intestinal transit and reduces visceral hypersensitivity. Data from a meta-analysis (4 RCTs containing 3122 patients) demonstrated that both 75 mg two times per day and 100 mg two times per day were superior to placebo using the FDA-approved composite end point for IBS-D, consisting of improvement in abdominal pain and stool consistency (RR 0.89; 95% CI 0.84 to 0.94 and RR 0.87; 95% CI 0.83 to 0.91, respectively) (online supplemental figure 10), global tendency (RR 0.89; 95% CI 0.84 to 0.94 and RR 0.87; 95% CI 0.83 to 0.91, respectively) (online supplemental figure 10), global symptoms and stool consistency (online supplemental figures 11 and 12). Eluxadoline 100 mg two times per day was also superior to placebo for abdominal pain (online supplemental figure 13). Adverse events included constipation, nausea and headache, and adverse events leading to drop out were significantly higher with active drug than placebo. Serious adverse events, including pancreatitis and sphincter of Oddi spasm, have been reported, occurring in 0.5% of patients in these trials. The drug is contraindicated in patients with prior sphincter of Oddi problems or cholecystectomy, alcohol dependence, pancreatitis or severe liver impairment. Although licensed for IBS-D, the drug is unavailable in many countries.

Drugs acting as antagonists at the 5-HT₃ receptor are also licensed for IBS-D. These include alosetron and ramosetron, which slow gastrointestinal transit, reduce visceral hypersensitivity and alter rectal compliance. In a previous meta-analysis, both alosetron 1 mg two times per day and ramosetron 2.5 μg or 5 μg once a day were superior to placebo across various end points, including the FDA composite end point for IBS-D (3 RCTs of alosetron 1 mg two times per day, 787 patients, RR 0.69; 95% CI 0.60 to 0.80, and 1 RCT of ramosetron 2.5 μg once a day, 348 patients, RR 0.78; 95% CI 0.67 to 0.91) (online supplemental figure 10). Both drugs were also more efficacious than placebo for global symptoms, abdominal pain and stool consistency (online supplemental figures 11-13). Adverse events included constipation, nausea and headache; patients assigned to both drugs were more likely to report adverse events than with placebo. Alosetron was withdrawn from the market in 2001 due to reports of ischaemic colitis. However, it was reintroduced in the USA via a risk evaluation and mitigation strategy, at a lower dose of 0.5 mg two times per day, for women with severe IBS-D. Rates of ischaemic colitis observed since reintroduction are similar to the background rate in female patients with IBS. Ramosetron is only available in Asia. There have been no reports of ischaemic colitis associated with the drug. Due to the limited availability of both alosetron and ramosetron, RCTs of ondansetron, a widely available 5-HT₃ receptor antagonist with a robust safety profile, have been conducted. A small crossover trial of ondansetron titrated from 4 mg once a day to a maximum of 8 mg three times a day demonstrated significantly higher rates of improvement in urgency, bloating and stool consistency, but not abdominal pain. A subsequent RCT of 12 mg once a day of bimodal release ondansetron also demonstrated superiority over placebo for improvement in stool consistency, but not abdominal pain. Constipation is the most common side effect. Results from a parallel-group RCT are awaited.

The efficacy of rifaximin, a non-absorbable antibiotic, has also been tested in IBS-D, on the basis that disturbances in the gastrointestinal microbiota may, in part, be responsible for symptoms. In a meta-analysis of 2 RCTs, which recruited 1260 patients, rifaximin 550 mg three times a day for 14 days was more efficacious than placebo for the FDA composite end point for IBS-D (RR 0.92; 95% CI 0.86 to 0.98) (online supplemental figure 10) and for stool consistency alone (online supplemental figure 12), but not for global symptoms or abdominal pain (online supplemental figures 11 and 13). Headache was the most common adverse event, but side effects were no more common with rifaximin than with placebo. Due to the modest efficacy, and concerns over the potential for adverse events (including *Clostridium difficile* infection and bacterial resistance) with repeated courses of rifaximin, FDA approval was not forthcoming. A subsequent ‘treatment’ trial was therefore conducted. In this RCT, patients received open-label rifaximin and were then randomised to two repeat 14-day courses of rifaximin or placebo if they experienced symptom relapse. Significantly more patients experienced an improvement in global symptoms with rifaximin after each treatment course, and there were no safety concerns. The drug is now licensed for IBS-D in the USA but is not available for this indication in many countries.

A network meta-analysis comparing the relative efficacy of all these licensed therapies for IBS-D, across various end points, demonstrated that alosetron 1 mg two times per day ranked first for the FDA composite end point for IBS-D and global symptoms (online supplemental figures 10 and 11), with ramosetron 2.5 μg once a day second. For the FDA composite end point, alosetron was superior to all treatments, except ramosetron 2.5 μg once a day. For abdominal pain, ramosetron 2.5 μg once a day and ramosetron 5 μg once a day were ranked first and second, respectively (online supplemental figure 13). Finally, for stool consistency alosetron 1 mg two times per day ranked first, with ramosetron 5 μg once a day second (online supplemental figure 12).

**Recommendations**

- Eluxadoline, a mixed opioid receptor drug, is an efficacious second-line drug for IBS with diarrhoea in secondary care. It is contraindicated in patients with prior sphincter of Oddi problems or cholecystectomy, alcohol dependence, pancreatitis or severe liver impairment, and lack of availability may limit its use (recommendation: weak, quality of evidence: moderate).

- 5-Hydroxytryptamine 3 receptor antagonists are efficacious second-line drugs for IBS with diarrhoea in secondary care. Alosetron and ramosetron are unavailable in many countries; ondansetron titrated from a dose of 4 mg once a day to a maximum of 8 mg three times a day is a reasonable alternative. Constipation is the most common side effect. This drug class is likely the most efficacious for IBS with diarrhoea (recommendation: weak, quality of evidence: moderate to high).

- The non-absorbable antibiotic rifaximin is an efficacious second-line drug for IBS with diarrhoea in secondary care, although its effect on abdominal pain is limited. The drug is
licensed for IBS with diarrhoea in the USA but is not available for this indication in many countries (recommendation: weak, quality of evidence: moderate).

**Drugs used second line for the treatment of IBS-C**

In patients with IBS-C who do not experience symptom improvement with laxatives, escalation to second-line drugs should be considered in secondary care. These fall into two main classes, secretagogues and 5-HT₄ agonists. Secretagogues, including linaclotide, lubiprostone, plecanatide and tenapanor activate ion channels on the intraluminal surface of enterocytes, resulting in an efflux of ions and water into the intestinal lumen, softening stools and accelerating transit.²³³ ²⁴⁰ Linaclotide is a peptide that acts as a guanylate cyclase-C agonist. Lubiprostone is a prostaglandin E₁ derivative, which activate chloride type 2 channels. Plecanatide is another guanylate cyclase-C agonist that binds in a pH-dependent manner, in contrast to linaclotide, such that the majority of its activity is confined to the proximal small bowel.²⁴¹ Tenapanor is a small molecule inhibitor of the gastrointestinal sodium-hydrogen exchanger-3. 5-HT₄ agonists, such as tegaserod, have prokinetic effects and also accelerate transit.²⁴² Abdominal bloating is a particularly troublesome symptom in patients with IBS-C,⁴⁶ and the effects of all these drugs on this symptom, other than plecanatide, has been assessed in some RCTs.

In an update of a previous meta-analysis,¹⁵⁵ a dose of 290 μg once a day linaclotide was superior to placebo in 5 RCTs, containing 3193 patients, for the FDA composite end point for IBS-C, consisting of improvement in abdominal pain and an increase of ≥1 CSBMs per week from baseline (RR 0.82; 95% CI 0.78 to 0.96) (online supplemental figure 14) and abdominal pain alone (online supplemental figure 15) in 4 trials containing 3061 patients (online supplemental figure 16). The drug was also superior to placebo in terms of an improvement in abdominal bloating in 4 trials containing 3061 patients (online supplemental figure 17). Adverse events were significantly more common with linaclotide 290 μg once a day, with diarrhoea being the most common. Lubiprostone 8 μg two times per day was superior to placebo for both the FDA composite end point for IBS-C (RR 0.87; 95% CI 0.78 to 0.96) (online supplemental figure 14) and abdominal pain alone (online supplemental figure 15) in this meta-analysis, using a post hoc analysis of data from 2 phase III RCTs, containing 452 patients.¹⁵⁵ The drug was superior to placebo for abdominal bloating in these 2 RCTs (online supplemental figure 17). Adverse events were no more common with lubiprostone, except for nausea. In the same meta-analysis,¹⁵⁵ both plecanatide 3 μg once a day and 6 μg once a day were superior to placebo for the FDA composite end point (RR 0.88; 95% CI 0.82 to 0.94 for 3 μg once a day in 3 RCTs, recruiting 1632 patients, and RR 0.87; 95% CI 0.81 to 0.93 for 6 μg once a day in 2 RCTs, containing 1461 patients) (online supplemental figure 14) and abdominal pain alone (online supplemental figure 15), but not for an increase of ≥1 CSBMs per week from baseline (online supplemental figure 16). Adverse events were significantly more frequent with plecanatide 3 μg once a day, compared with placebo, and diarrhoea was significantly more likely with both doses. Finally, 3 RCTs of tenapanor 50 mg two times per day, recruiting 1428 patients, were included in this meta-analysis.¹⁵⁵ The RR for the FDA composite end point, compared with placebo, was 0.85 (95% CI 0.79 to 0.92) (online supplemental figure 14). The drug was also more efficacious than placebo for abdominal pain (online supplemental figure 15) and an increase of ≥1 CSBMs per week from baseline (online supplemental figure 16). Again, the drug was more likely to improve abdominal bloating than placebo in 3 trials containing 1428 patients (online supplemental figure 17). Except for diarrhoea, adverse events were no more likely with the drug than with placebo.

A previous meta-analysis of 11 RCTs demonstrated that tegaserod was superior to placebo for the treatment of IBS-C in 9242 patients (RR 0.85; 95% CI 0.80 to 0.90) (online supplemental figure 18).³⁶³ Diarrhoea was the most common adverse event and was significantly more likely than with placebo. Due to a small excess number of cerebrovascular and cardiovascular ischaemic events in patients taking the drug, it was withdrawn in 2007. Tegaserod was reintroduced in the USA in 2018 for female patients <65 years of age with IBS-C without pre-existing cardiovascular disease, based on a post hoc analysis of 3 large trials reporting efficacy according to the FDA composite end point for IBS-C. In a meta-analysis using data from these 3 trials, containing 2472 patients, the drug was superior to placebo (RR 0.85; 95% CI 0.80 to 0.91) (online supplemental figure 14).¹⁵⁴ Finally, tegaserod was superior to placebo for abdominal bloating in 4 RCTs, containing 5132 patients (online supplemental figure 17). Although prucalopride, which is a highly selective 5-HT₃ agonist with no known cardiovascular or cerebrovascular safety concerns, is efficacious in the treatment of chronic idiopathic constipation,²²⁰ to date there have been no RCTs in IBS-C.

A network meta-analysis examining the relative efficacy of secretagogues and tegaserod across 18 RCTs, in 10 638 patients, demonstrated that all drugs were superior to placebo.¹⁵⁴ ¹⁵⁵ Linaclotide 290 μg once a day ranked first across all end points, including abdominal bloating (online supplemental figure 14-16 and online supplemental figure 19), but on indirect comparison of active treatments there were no significant differences between individual drugs and dosages.

**Recommendations**

- Linaclotide, a guanylate cyclase-C agonist, is an efficacious second-line drug for IBS with constipation in secondary care. It is likely to be the most efficacious secretagogue available for IBS with constipation, although diarrhoea is a common side effect (recommendation: strong, quality of evidence: high).
- Lubiprostone, a chloride channel activator, is an efficacious second-line drug for IBS with constipation in secondary care. This secretagogue is less likely to cause diarrhoea than others. However, patients should be warned that nausea is a frequent side effect (recommendation: strong, quality of evidence: moderate).
- Plecanatide, another guanylate cyclase-C agonist, is an efficacious second-line drug for IBS with constipation in secondary care. Diarrhoea is a common side effect and is no less likely than with linaclotide or tenapanor. Although the drug is licensed for IBS with constipation in the USA, it is not yet available for this indication in many countries (recommendation: strong, quality of evidence: high).
- Tenapanor, a sodium-hydrogen exchange inhibitor, is an efficacious second-line drug for IBS with constipation in secondary care. Again, diarrhoea is a frequent side effect. Although the drug is licensed for IBS with constipation in the USA, it is not yet available for this indication in many countries (recommendation: strong, quality of evidence: high).
- Tegaserod, a 5-Hydroxytryptamine 4 receptor agonist, is an efficacious second-line drug for IBS with constipation in secondary care.
secondary care but is unavailable outside the USA. Diarrhoea is a common side effect (recommendation: strong, quality of evidence: moderate).

**Psychological therapies**

A recent network meta-analysis of RCTs of psychological therapies for IBS demonstrated that several psychological therapies were more efficacious than control interventions. However, the most compelling evidence, based on the number of trials and long-term outcomes was for CBT and gut-directed hypnotherapy, both of which are recommended by the NICE guideline when symptoms have not improved after 12 months of drug treatment.

The principles of CBT are based on the five systems model, which suggests that cognitions (thoughts), behaviours (actions), emotions and physiology all interact within the context of the broader environment or social system. By altering any of these systems, others can potentially be modified (eg, changing one’s thoughts can alter one’s emotions, as well as one’s physiological responses). Although there is a core set of defined therapeutic techniques employed in all variants of CBT, the underlying formulations of the therapy differ, depending on the primary outcome. For instance, if reducing depression is the primary outcome the therapy focuses on increasing pleasurable activities and challenging alternative negative thoughts about the self. If anxiety is the outcome, the therapy focuses on reducing avoidance of threatening situations and threat-related thought patterns.

The network meta-analysis of psychological interventions for IBS, which included 15 trials of CBT in 1844 patients, concluded that CBT delivered in several formats was more effective than a control, including education and support, treatment as usual, and a waiting list control (online supplemental figure 20). Face-face CBT (10 RCTs, 930 patients, RR 0.62; 95% CI 0.48 to 0.80), self-administered or minimal contact CBT (4 trials, 434 patients, RR 0.61; 95% CI 0.43 to 0.83), therapist-delivered CBT over the telephone (1 RCT, 373 patients, RR 0.50; 95% CI 0.29 to 0.84) and group CBT (2 trials, 50 patients, RR 0.41; 95% CI 0.19 to 0.91) were all superior to a waiting list control. There was substantial heterogeneity in some of the estimates, which may, in part, be explained by differences in trial design, sample size and whether patients with refractory IBS were included. Analysis of trials that only included patients with refractory symptoms reduced the heterogeneity, and still demonstrated efficacy for CBT in some formats (online supplemental figure 21).

Other sources of heterogeneity may include hours of therapy time. For example, within the face-to-face CBT groups therapist time ranged from 5 to 12 hours. Of the two web-based interventions, one had eight online interactive sessions with 2.5 hours of telephone therapist support, and the other five online sessions with email support. There were also differences in the skill level of therapists across trials. Most were experienced CBT therapists, but some trials used doctoral-level students, and one RCT trained nurses to deliver CBT. The CBT protocols themselves varied. Some made IBS-specific modifications to existing mental health protocols, and others were based on stress management related to IBS.

The most recent, and largest, RCTs used CBT developed specifically for IBS. In both, this included education concerning the role of stress in IBS, stress management techniques, cognitive techniques to identify and challenge both unhelpful thoughts associated with IBS and core beliefs around perfectionism, and relapse prevention. The ACTIB trial also included a description of the pathophysiology of key symptoms, and how CBT may work through the gut-brain axis. Other sections focused on altering IBS-specific safety and avoidance behaviours (eg, not going out until bowels are empty, or a toilet location is known) and managing negative emotions. The IBOS trial included problem-solving training focused on coping with IBS stressors.

The rationale for IBS-specific CBT is further supported by a review of the psychological mechanisms of CBT for IBS. Key mechanisms related to reduction in IBS symptom severity appear to be changes in IBS-specific cognitions and gastrointestinal-specific anxiety, rather than changes in general anxiety. With respect to this issue, it is worth noting that in the largest trial of CBT for IBS conducted to date at least 50% of patients met cutoffs for probable common mental disorders at baseline, and both therapist-delivered CBT over the telephone and web-based CBT using IBS-specific protocols reduced anxiety and depression scores at all follow-up points. These data suggest that treatment with IBS-specific CBT protocols may benefit both mental health and gastrointestinal symptoms.

The network meta-analysis suggested that therapist-delivered CBT over the telephone had a larger effect on IBS symptoms at follow-up than web-based CBT. However, in the ACTIB trial, health economic analysis suggested web-based CBT was the more cost-effective option. In this trial, the web-based intervention used the same protocol as the therapist-delivered CBT over the telephone, but the eight sessions were delivered on an interactive, tailored, website. Patients worked through this on their own at home, with guided telephone support from the therapist. The network meta-analysis also demonstrated that therapist-delivered CBT over the telephone, web-based CBT, face-to-face CBT and self-administered or minimal contact CBT were all superior to treatment as usual after 12 months of follow-up (online supplemental figure 22). It is likely that these approaches have similar efficacy, but more work is needed to determine cost-effectiveness of the various modes of delivery. One advantage of web-based therapies is that they are easy to standardise at scale and monitor usage. However, the disadvantage is that they tend to have lower adherence.

Evidence suggests, therefore, that CBT for IBS is effective in both high-intensity (therapist-delivered) and minimal contact (therapist-guided) formats, as well as self-administered with either bibliographic material or web-based. There is also some evidence for group CBT, but more trials are needed to confirm this. As the ACTIB trial suggested a bigger treatment effect with therapist-delivered treatment, but that this was less likely to be cost-effective, a stepped care approach may provide greatest benefit, where patients with more complex needs receive face-to-face CBT, and those with milder symptoms are offered web-based or other guided, supported versions.

Despite an evidence base for use, many psychological therapies are not widely available, despite being recommended in the NICE guideline for patients with ongoing symptoms after 12 months of drug treatment. However, with the success of the ACTIB and IBOS trials, there have been improved training opportunities for therapists, and therapist manuals made freely available to Improving Access to Psychological Therapy (IAPT) services in the UK, on completion of a specified training programme. Telephone and web-based delivery of CBT also has the potential to further increase access. The IAPT service has, therefore, increased its remit to include CBT for IBS, and patients can be referred via general practitioners or can self-refer. More work is needed to enhance and standardise
the training programme providers to ensure IAPT expertise in this area. Therapists without specific IBS training tend to default to using mental health treatments, which can disengage patients with IBS. Therefore, referrals should specify that this is for IBS-specific CBT.

Gut-directed hypnotherapy is one of the psychological therapies for IBS with the largest evidence base for both short-term and long-term efficacy in RCTs. The aims of this are to induce a deep state of relaxation in order to teach the patient new skills for self-management and control of their gut function. The treatment is delivered using IBS-specific protocols, which incorporate combinations of a variety of techniques including imagery, metaphors, tactile approaches to alleviate pain and diaphragmatic breathing specifically targeting abdominal bloating and distension. One of the strengths of the treatment is that the content can be tailored according to the patient’s symptom profile. Although the exact mechanisms of its effects in IBS remain uncertain, hypnotherapy modulates the gut-brain axis, with several studies demonstrating positive changes in gut-brain function before, and immediately after, hypnotherapy, including modulation of postprandial gastro-colic reflex activity, altered colonic motility, reduced visceral hypersensitivity, and normalisation of gut-brain pain processing signals on functional brain imaging. Traditionally, hypnotherapy for IBS has been delivered via between 6 and 12 face-to-face weekly sessions of individualised treatment with a trained therapist. This approach has been shown to be efficacious; a meta-analysis of 6 RCTs, recruiting 639 patients, reported a RR of remaining symptomatic of 0.73 (95% CI 0.55 to 0.97) compared with education and/or support and 0.67 (95% CI 0.49 to 0.91) compared with a waiting list control (online supplemental figure 20). Moreover, in the largest clinical series to date, including 1000 patients, >75% of patients achieved a clinical response to hypnotherapy, defined as a ≥50% reduction in healthcare utilisation in both primary and secondary care, with similar response rates in children and adolescents with IBS. Hypnotherapy has previously only been recommended for patients with IBS when symptoms are refractory to conventional treatments. Indeed, a meta-analysis of RCTs has shown that gut-directed hypnotherapy is one of the few treatments that performs better than a control for patients with refractory symptoms (online supplemental material 21). However, its clinical efficacy has also been demonstrated in non-refractory populations, and clinical outcomes in children and adolescents with IBS suggest that use of gut-directed hypnotherapy at an earlier stage of the condition may be beneficial.

One of the barriers to wider scale provision of gut-directed hypnotherapy, and its current restriction to refractory cases, may be the cost of its delivery, including time intensity, and the requirement for a trained therapist. However, intervention with gut-focused hypnotherapy has been shown to have wider socioeconomic benefits including improving general well-being, reductions in healthcare utilisation in both primary and secondary care, reduced presenteeism at work, improved quality of life, and long-term beneficial effects on symptoms, making it a potentially cost-effective option. Patients with IBS in tertiary care with severe functional limitations may require individualised hypnotherapy, with the content of sessions customised to their symptom profiles. However, patients in primary or secondary care may benefit from accessing a more ‘generic’ form of group-delivered hypnotherapy. In a large, multicentre, RCT in patients with IBS in primary or secondary care, group hypnotherapy was shown to be non-inferior to individual hypnotherapy. Group hypnotherapy may therefore have a role in primary and secondary care settings, with the potential advantage that this approach could reduce delivery costs and improve access. Early reports of clinical outcomes via video-consultation are also promising, with similar response rates achieved, compared with face-to-face treatment. The offer of psychological therapies should not be limited to patients with psychological comorbidities. IBS symptoms are inherently distressing so there are often symptoms of anxiety and depression in IBS, but these are not necessarily at case level for a diagnostic classification. Nevertheless, it may be worthwhile screening for evidence of both in the clinic, using a simple questionnaire, such as the General Anxiety Disorder assessment-7 and the Patient Health Questionnaire-9, and discussing referral to a mental health service or psychiatrist if mood is felt to be the key issue. The majority of the trials of psychological therapies conducted to date include a wide range of patients with IBS, many of whom would also not have met the threshold for a psychiatric disorder. In contrast to psychological treatments used for psychiatric disorders, which focus on mood, the IBS-specific therapies discussed here focus on brain-gut symptom-specific treatment mechanisms. The primary aim of treatment is to reduce severity and impact of abdominal pain and to help regulate bowel habit. They should, therefore, be viewed as behavioural methods for managing and treating IBS symptoms, rather than as psychotherapies.

Recommendations

- IBS-specific cognitive behavioural therapy may be an efficacious treatment for global symptoms in IBS (recommendation: strong, quality of evidence: low).
- Gut-directed hypnotherapy may be an efficacious treatment for global symptoms in IBS (recommendation: strong, quality of evidence: low).
- Psychological therapies should be considered when symptoms have not improved after 12 months of drug treatment. Referral can be made at an earlier stage, if accessible locally, and based on patient preference (recommendation: strong, quality of evidence: low).

Approach to the patient with severe or refractory symptoms

Severe IBS lacks a precise consensus definition, but is considered to be a biopsychosocial composite of patient-reported gastrointestinal and extraintestinal symptoms, degree of disability, illness-related perceptions and behaviours, insufficient response to conventional treatments and high healthcare utilisation. Refractory IBS is a related, but distinct term, again with no consensus definition, which is taken to mean patients whose symptoms have not improved with interventions, some of whom may also have severe symptoms. Validated severity scoring systems to assess impact and severity of IBS symptoms include the IBS severity scoring system, the gastrointestinal symptom rating scale-IBS and the functional bowel disorder severity index. In one European study, approximately one in four individuals with IBS were categorised as severe in a general population setting. Although the risk of missing, or subsequently developing, an organic disorder in patients diagnosed with IBS is low, this rate may be increased in those with severe symptoms, and should prompt a review of the diagnosis, with consideration of further targeted investigation. Nevertheless, it is important to stress that in most patients a diagnosis of IBS is secure, and further repeated investigations have a low yield.
should also be distinguished from other severe functional gastrointestinal disorders that may have overlapping symptom presentations, including the narcotic bowel syndrome, if the patient is taking long-term opioids, centrally mediated abdominal pain syndrome, and small intestinal dysmotility. Referral to a multidisciplinary chronic pain team to aid pain management and help with opioid reduction should be considered if abdominal pain becomes centrally-mediated or if narcotic bowel syndrome develops.

A large and diverse range of dietary, microbial, traumatic, interpersonal, genetic, psychological, physiological, psychiatric and functional comorbidity factors have been described in patients with severe IBS. Consequently, it is unlikely that a single targeted intervention will be transformative and a multidimensional, multisystem and integrated multidisciplinary team approach is usually required. Although there is a limited evidence base to guide management of this group of patients, as most RCTs do not differentiate response to treatment according to baseline symptom severity, there is recent trial data reporting superior outcomes with an integrated approach involving gastroenterologists, dietitians and clinical psychologists, rather than a gastroenterologist alone. There is a danger that, in this vacuum, ‘alternative’ therapies with the least evidence for their efficacy and safety are recommended by physicians or other practitioners, or are sought out by patients.

Patients with IBS with severe symptoms are more willing to accept significant medication risks, for example, a mean 1% chance of sudden death in return for a 99% chance of cure of their symptoms with a hypothetical medication. Furthermore, patients are at increased risk of iatrogenic harms, through unnecessary surgery, including hysterectomy, appendicectomy and cholecystectomy, and inappropriate prescribing of opioids. The first principle of care for this vulnerable population of patients should therefore be primum non nocere—first do no harm. This includes harm from unregulated and unproven approaches, especially if incentivised by financial or reputational gain.

Interventions with reported efficacy for patients with undifferentiated IBS specifically classified as severe or refractory include CBT, integrative group therapy, gut-directed hypnotherapy, gut-brain neuromodulators or psychodynamic interpersonal therapy. For severe or refractory IBS-C, surgical management, consisting of a potentially reversible temporary loop ileostomy, with a view to colectomy if stoma function results in improved, rather than worsened, quality of life for the appropriately screened patient, the ileal bile acid transporter inhibitor elobixibat, or linaclootide, all have some evidential support. For severe or refractory IBS-D, alosetron has regulatory approval in the USA for women. In the UK, a reasonable alternative might be ondansetron although, to date, this has not yet been confirmed to be efficacious in severe or refractory IBS. For severe or refractory abdominal pain one study reported efficacy with intramuscular hyoscine.

Other IBS guidelines suggest the use of combination gut-brain neuromodulators, termed augmentation, for more severe symptoms. Evidence from a large cohort of patients with severe chronic continuous abdominal pain showed that combinations of neuropathic analgesics (eg, duloxetine plus gabapentin) were more efficacious than monotherapy. Vigilance for the development of the serotonin syndrome for some combinations, especially those involving both SSRIs and SNRIs, is required. Symptoms include fever, hyperreflexia, tremor, sweating and diarrhoea. For patients with symptoms that are refractory to these pharmacological therapies, and those who have comorbid conditions or psychological symptoms, a combination of a gut-brain neuromodulator and psychological therapy may be more efficacious than monotherapy with either, drawing parallels with evidence from the depression and chronic headache literature.

**Recommendations**

- Severe or refractory IBS symptoms should prompt a review of the diagnosis, with consideration of further targeted investigation (recommendation: weak, evidence: very low).
- Severe or refractory IBS should be managed with an integrated multidisciplinary approach (recommendation: weak, evidence: very low).
- Iatrogenic harms due to opioid prescribing, unnecessary surgery and unproven unregulated diagnostic or therapeutic approaches incentivised by financial or reputational gain should be avoided (recommendation: strong, evidence: very low).
- Use of combination gut-brain neuromodulators, termed augmentation, may be considered for more severe symptoms, with vigilance for risks of serotonin syndrome (recommendation: weak, evidence: very low).

**Drugs in development**

The highly selective 5-HT3 agonist minesaprade has been studied in 2 phase II dose-ranging RCTs in patients with IBS-C. A dose of 40 mg once a day was superior to placebo, in terms of improvements in number of bowel movements per week, abdominal pain and global symptoms. The drug was well-tolerated, with diarrhoea the most common side effect, and there were no cardiovascular adverse events. Histamine has a potential role in mediating visceral hypersensitivity, and in a small RCT in 45 patients the histamine, receptor antagonist ebastine led to significant improvements in both abdominal pain and global symptoms. A larger trial in 200 patients is ongoing (NCT01908465). Novel drugs that have been tested successfully in chronic idiopathic constipation, including elobixibat and mizagliblozin, a sodium-glucose cotransporter-1 inhibitor, are likely to undergo testing in IBS-C. Some secretagogues, including linaclootide, stimulate cyclic GMP production, which can attenuate visceral pain. An RCT of delayed-release linaclootide, with action confined to the ileo-caecal region of the gastrointestinal tract, demonstrated significant effects on abdominal pain, with lower rates of diarrhoea than convention-release linaclootide. Other novel approaches include drugs that act on cannabinoid receptors, which are expressed in the gastrointestinal tract and may also modulate pain expression. The cannabinoid type-2 receptor agonist, olorinab, has been tested in patients with quiescent Crohn’s disease, and led to reductions in abdominal pain and improved bowel movements; a trial in IBS is underway (NCT04043455).

**Other treatments in development**

In recent years, there has been considerable interest in the evaluation of faecal microbiota transplantation (FMT) for IBS. Unfortunately, a meta-analysis of 5 RCTs, containing 267 patients, demonstrated no significant benefit of FMT compared with placebo (RR 0.98; 95% CI 0.58 to 1.66), and in 2 pooled trials placebo capsules administered orally were superior to capsules containing donor stool (RR 1.96; 95% CI 1.19 to 3.20). Criticisms of the trials, to date, have included small sample sizes, heterogeneity in IBS subtypes recruited, lack of standardisation of donor samples and suboptimal end points used. There is
therefore a need for further, large, high-quality trials of FMT for IBS, perhaps targeting subgroups of patients with evidence of dysbiosis, who may be more likely to benefit. At present, therefore, there is insufficient evidence to recommend FMT for IBS outside of a research setting. Enterosgel, an intestinal adsorbent approved for use in IBS-D and available over-the-counter in the UK is currently the subject of a multicentre RCT in IBS-D.293 For IBS-C, there are ongoing trials of an exo-peristalsis device.294

Future research priorities are outlined below.

RESEARCH: BARRIERS, PRIORITIES AND IMPLICATIONS FOR FUTURE STUDY DESIGN

Current treatments for IBS are often inadequate and many patients remain unsatisfied with medical care.91,92,95 Despite this, and the high prevalence of IBS, the pipeline of new treatments is relatively poor. This is related to several factors, including the challenges of running large RCTs, high thresholds for licensing of therapies and relatively low levels of academic funding, as IBS is not viewed as a priority by funders.297 The negligible mortality associated with IBS,148 together with the association with common mental disorders,119 and the stigmatisation of the condition,106 107 likely contribute to the latter. More research is required to understand the burden of suffering of patients with IBS and the direct consequences to daily life. With such a prevalent condition, it should be relatively straightforward to recruit to large RCTs, but these have often recruited slowly, and sometimes failed. This leads to a waste of both resources and participant time invested. The consequent failure to evaluate treatment efficacy adequately limits availability of potentially useful therapies.

These failings also have indirect effects, leading to reduced confidence of funders and sponsors, making trials of other therapies more challenging. There are three critical reasons for difficulty recruiting to IBS trials. First, highly restrictive inclusion criteria reduce the eligible population. Among individuals who believe themselves to have IBS, only around 60% fulfil Rome IV criteria, whereas 80% fulfil Rome III.23 There are often severity criteria built in, which aim to exclude the most severe or refractory symptoms, as well as less severe cases. In addition, many treatments are restricted to patients with IBS-C or IBS-D, whereas those with IBS-M or IBS-U are rarely recruited; indeed, although there are established composite end points for IBS-C and IBS-D, these do not exist for IBS-M or IBS-U. Second, recruitment to trials is optimal when patients are linked to specialist clinics. However, patients with IBS are widely disseminated, mostly in community care, often with no long-term follow-up, and only a minority attend specialist clinics where research is undertaken. This latter group is often more complex, more refractory and, by definition, less appropriate for treatment trials. Third, patient and public involvement exercises have identified that trial protocols are onerous and unrealistic. There are often too many visits, a need for invasive investigations, and a high burden of data collection. Patients who enter IBS trials have usually tried all available treatments and remain unsatisfied with care, so being randomised to ‘standard care’ for ≥12 weeks is unappealing.

Future trial design needs to take these issues into consideration, using a pragmatic and participant-focused approach. Inclusion criteria should be consistent with the population that will receive the treatment. If studying a safe over-the-counter treatment, restricting inclusion to only those meeting Rome IV criteria is questionable. As with our recommendations for diagnosis, emphasising a more pragmatic clinical definition of IBS, together with limited need for investigations, the same principles should apply to trial eligibility. This would allow faster recruitment to RCTs, provide equity of access for patients and give a better indication of the true benefit of treatments being studied in the population most likely to use them. Trials should include an open-label phase, wherever possible, to allow access to the active treatment for all participants, with data collection limited to that necessary to prove efficacy and avoid use of multiple secondary academic objectives.

Recruitment methods need to include community-based approaches, involving primary care settings, social media campaigns and consent-for-contact registries. The geographical exclusion produced by site-dependent recruitment can be overcome by a remote access, or virtual, approach.298 IBS research is leading the way in this regard with the first UK interventional virtual trial being conducted in IBS, demonstrating that virtual recruitment methods outperform site-dependent recruitment significantly.295 296 Although RCTs remain the gold standard, they have many weaknesses, and modern methods of trial design may be more suitable to studying IBS. The use of virtual controls, artificial intelligence and big data solutions, together with meaningful real-time outcome data should be considered. Some important areas of research are listed below, but this is not exhaustive, will change over time and needs to be informed by a priority-setting partnership.

Recommendations

► Successful completion of large clinical trials will require pragmatic inclusion criteria, minimisation of the participant trial burden and effective recruitment strategies that reach into community settings. Virtual (remote access) trial approaches will reduce geographical exclusion.

► A priority-setting partnership would best discern valuable research questions.

► Some future research themes include, but are not limited to:
  – Characterisation of the illness to understand predictors (clinical, genetic, psychological and biological) of outcome and treatment response, determinants of refractory illness and burden of illness (particularly with respect to workplace productivity) by conducting large-scale epidemiological studies with extended observation.
  – Trials of novel treatments, including pharmacological, dietary and behavioural therapies, device-based treatments and faecal microbiota transplantation. There is also a need for development of visceral analgesics. Consideration should be given to stratifying randomised controlled trials by IBS severity and subtype, burden of extraintestinal symptoms and psychological comorbidity.
  – A better understanding of treatment combinations to uncover augmentation effects between therapies, and to assess the value of multidisciplinary approaches.
  – Modulation of pain and psychological responses using pharmacological (eg, serotonin norepinephrine reuptake inhibitors) or behavioural approaches (eg, cognitive-behavioural therapy used earlier in the disease course or via digital provision), and comparison of cognitive-behavioural therapy with gut-directed hypnotherapy.
  – Med-tech approaches (web-based, apps and devices) to behavioural modification.

CONCLUSIONS

This guideline has summarised current evidence regarding the diagnosis and management of IBS and is intended to be a practical guide for clinicians seeing patients with the condition. IBS
is a multifactorial disorder of gut-brain interaction, and the evidence summarised here underlines the importance of effective communication, making a positive diagnosis, and instituting appropriate, evidence-based pharmacological and psychological therapies according to predominant symptoms, global patient assessment and patient choice, in order to improve both symptoms and quality of life within a bio-psycho-social framework. This guideline has also highlighted emerging new therapeutic options for IBS and priority areas for ongoing research.

Author affiliations

1Neurogastroenterology Unit, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK
2Division of Diabetes, Endocrinology and Gastroenterology, University of Manchester, Manchester, UK
3Gastroenterology, Salford Royal Foundation Trust, Salford, UK
4Leeds Gastroenterology Institute, Leeds Teaching Hospitals NHS Trust, Leeds, UK
5Institute of Biomedical & Clinical Sciences, University of Leeds, Leeds, UK
6Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA
7Primary Care and Population Sciences, University of Southampton, Southampton, UK
8Nottingham Digestive Diseases Biomedical Research Unit, University of Nottingham, Nottingham, UK
9Gastroenterology, Doncaster and Bassetlaw Hospitals NHS Trust, Armthorpe Road, Doncaster, UK
10Academic Unit of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
11Department of Gastroenterology, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, UK
12Department of Gastroenterology, Keele University, Keele, UK
13Gastroenterology, University of Edinburgh, Edinburgh, UK
14Psychology, King’s College London, London, UK
15Department of Gastroenterology, County Durham and Darlington NHS Foundation Trust, Durham, UK
16Leeds Gastroenterology Institute, St James’s University Hospital, Leeds, UK

Twitter Dipesh H Vasant @DipeshVasant:, Christopher J Black @DrCJBlack and Alexander C Ford @alexford12399

Acknowledgements We are grateful to Julie Thompson, Information Manager at Guts UK, and Margaret Elizabeth Ogden, Michael Prior, John Shaw and Stevie Vaneghan from the Patient Advisory Group, Nottingham Biomedical Research Centre and Nottingham University Hospitals NHS Trust, Gastrointestinal and Liver Theme, for reading this guideline and providing feedback from the patient perspective.

Contributors DHV, PAP, CIB, LAH, HE, MC, AA, IA, ADE, MPE, RM-M, YY and ACF conceived and drafted the study. All authors drafted the manuscript. ACF, DHV and PAP edited the manuscript. All authors commented on drafts of the manuscript. All authors have approved the final draft of the manuscript.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests Please see the attached supplement of declarations of conflicts of interest for all authors.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMI. BMI disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

ORCID iDs

Dipesh H Vasant http://orcid.org/0000-0002-2329-0616
Christopher J Black http://orcid.org/0000-0001-5499-3603
Lesley A Houghton http://orcid.org/0000-0002-5351-0229
Imran Aziz http://orcid.org/0000-0003-3833-2302
Alexander C Ford http://orcid.org/0000-0001-6371-4359

REFERENCES

Guidelines


98 Boyce PM, Colosimo NA, Talley NJ. Irritable bowel syndrome according to varying diagnostic criteria: are the new Rome II criteria unnecessarily restrictive for research and practice? Am J Gastroenterol 2000;95:3176–83.


131 Yu D, Cheeseman E, Vanner S. Combined orocaecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS. Gut 2011;60:334–40.


Published online as 10.1136/gutjnl-2022-324598 on 26 April 2021. Downloaded from http://gut.bmj.com/ on September 23, 2023 by guest. Protected by copyright.


Biopsies from patients with irritable bowel syndrome (IBS) have revealed a dysbiosis characterized by an overgrowth of certain bacteria, particularly Bacteroides and Firmicutes. This dysbiosis is thought to contribute to the symptoms of IBS, such as abdominal pain, bloating, and altered bowel habits. The gut microbiota plays a crucial role in the maintenance of gut health, and alterations in the gut microbiota have been associated with various gastrointestinal disorders, including IBS.

Several studies have reported that individuals with IBS have a different gut microbiota composition compared to healthy controls. For example, a study published in *Gastroenterology* in 2016 observed a significant decrease in the abundance of Bacteroides and an increase in the abundance of Firmicutes in patients with IBS. Similarly, a meta-analysis published in *Nutrition & Biologics* in 2017 found that patients with IBS had a higher abundance of Bacteroides and a lower abundance of Faecalibacterium prausnitzii compared to healthy controls.

The gut microbiota influences the immune system, inflammation, and the gut-brain axis, which are all implicated in the pathophysiology of IBS. The gut microbiota also plays a role in the regulation of the gut barrier, which is disrupted in IBS. The gut barrier is responsible for preventing the entry of luminal contents into the bloodstream, and its dysregulation can lead to systemic inflammation and immune activation.

Several studies have investigated the role of the gut microbiota in the pathophysiology of IBS and have suggested potential therapeutic interventions. For example, a study published in *Gut* in 2015 reported that patients with IBS had a lower abundance of the gene encoding the cytokine IL-17A, which is involved in inflammation, compared to healthy controls. The authors suggested that this finding could explain the inflammatory symptoms observed in IBS.

Another study published in *Gastroenterology* in 2016 found that patients with IBS had a higher abundance of the gene encoding the enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1), which is involved in the detoxification of toxins, compared to healthy controls. The authors suggested that this finding could explain the increased susceptibility to gut inflammation in IBS.

In conclusion, the gut microbiota plays a crucial role in the pathophysiology of IBS and represents a potential therapeutic target. Further research is needed to elucidate the mechanisms underlying the dysbiosis in IBS and to develop effective therapeutic interventions.
Gut: first published as 10.1136/gutjnl-2021-324598 on 26 April 2021. Downloaded from http://gut.bmj.com/ on September 23, 2023 by guest. Protected by copyright.